Fibrillar aggregations of pathogenic pro-vasopressin mutants by Birk, Julia






Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 





































Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
Prof. Dr. Martin Spiess 
Prof. Dr. Hans-Peter Hauri 
PD Dr. Jonas Rutishauser 
 
Basel, den 10. November 2009 
 
       Prof. Dr. Eberhard Parlow 
       Dekan 
 
   3 
Acknowledgements 
 
I would like to express my gratitude to: 
 
Prof. Dr. Martin Spiess for giving me the opportunity to perform this work in his lab 
 
PD Dr. med. Jonas Rutishauser for entrusting me with this project and for his support 
and guidance 
 
Michael Friberg for great teamwork on this project and beneficial discussions 
 
Cristina Prescanotto-Baschong for excellent electron microscopy, protein purification 
and good collaboration on this project 
 
Nicole Beuret for valuable discussions and professional technical assistance 
 
All the lab members: Lucyna Kocik, Tina Junne-Bieri, Barry Shortt, David 





   4 
Table of contents 
1 General Introduction .......................................................................................... 8 
1.1 Water homeostasis .................................................................................................... 8 
1.2 Diabetes insipidus .....................................................................................................10 
1.2.1 Neurohypophyseal diabetes insipidus...................................................................10 
1.2.2 Vasopressin precursor ..........................................................................................12 
1.2.3 ER retention of mutant vasopressin precursors ....................................................13 
1.3 The secretory pathway ..............................................................................................15 
1.3.1 ER entry ...............................................................................................................15 
1.3.2 Quality control ......................................................................................................15 
1.3.3 ER associated degradation (ERAD) .....................................................................17 
1.3.4 ER Stress .............................................................................................................18 
1.3.5 ER export and ERGIC ..........................................................................................20 
1.3.6 Intra Golgi transport ..............................................................................................22 
1.3.7 Granule formation .................................................................................................23 
1.4 Neurodegeneration ...................................................................................................25 
1.5 Neurotoxicity in ADNDI .............................................................................................28 
1.6 Aim of this thesis .......................................................................................................30 
2 Part I: Dominant pro-vasopressin mutants that cause diabetes insipidus 
form disulfide-linked fibrillar aggregates in the endoplasmic 
reticulum .............................................................................................. 32 
2.1 Summary ..................................................................................................................33 
2.2 Introduction ...............................................................................................................33 
2.3 Results ......................................................................................................................35 
2.3.1 Secretion-deficient dominant mutants form disulfide-linked homo-oligomers ........35 
2.3.2 Dominant pro-vasopressin mutants progressively accumulate as ER-associated 
aggregates ...........................................................................................................38 
2.3.3 Mutant pro-vasopressin aggregates show filamentous ultrastructure ....................42 
2.3.4 Purified pro-vasopressin spontaneously forms fibrils after removal of denaturant .46 
2.3.5 Cysteine residues are required for aggregate formation .......................................47 
2.4 Discussion ................................................................................................................50 
2.4.1 Dominant pro-vasopressin mutants cause ER retention due to misfolding ............50 
2.4.2 Mutant pro-vasopressins form disulfide-linked homo-oligomers, fibrils and large 
aggregations.........................................................................................................51 
2.4.3 A model for the formation of fibrillar aggregates in the ER ....................................51 
2.4.4 Role of aggregates for cytotoxicity ........................................................................54 
   5 
2.5 Materials and methods ..............................................................................................55 
2.5.1 Plasmids and constructs .......................................................................................55 
2.5.2 Cell culture and transient transfection ...................................................................55 
2.5.3 Metabolic labeling and immunoprecipitation .........................................................56 
2.5.4 Analysis of disulfide-linked oligomers ...................................................................56 
2.5.5 Immunofluorescence ............................................................................................57 
2.5.6 Electron microscopy .............................................................................................57 
2.5.7 Bacterial expression and in vitro fibril formation ....................................................58 
3 Part II: Aggregates of mutant vasopressin precursors: an amyloid-like 
structure? ............................................................................................. 60 
3.1 Introduction ...............................................................................................................60 
3.1.1 Amyloids ...............................................................................................................60 
3.1.2 Disruption of β-sheets by proline insertions ..........................................................61 
3.1.3 Proline substitution in pro-vasopressin .................................................................63 
3.2 Material and methods ................................................................................................64 
3.2.1 Cloning strategy: ..................................................................................................64 
3.2.2 Cultivation and Transient Transfection of COS-1 cells ..........................................65 
3.2.3 Metabolic labeling and immunoprecipitation .........................................................65 
3.2.4 Metabolic labeling and non-reducing immunoprecipitation ....................................66 
3.2.5 Immunofluorescence ............................................................................................66 
3.3 Results ......................................................................................................................67 
3.3.1 Proline replacements cause retention of the precursor in the ER but do not prevent 
the formation of disulfide-linked oligomers ............................................................67 
3.3.2 Proline insertion within the vasopressin domain inhibit formation of large 
aggregates ...........................................................................................................69 
3.4 Discussion ................................................................................................................71 
3.4.1 Insertion of 10 prolines and glycines inhibits the formation of large aggregates ....71 
4 Part III: Molecular analysis of novel mutations causing autosomal dominant 
neurohypophyseal diabetes insipidus............................................... 73 
4.1 Introduction ...............................................................................................................73 
4.2 Material and methods ................................................................................................73 
4.2.1 Genomic DNA analysis in ADNDI patients ............................................................73 
4.2.2 Plasmids and constructs .......................................................................................74 
4.2.3 Cell culture and transient transfection ...................................................................75 
4.2.4 Metabolic labeling and immunoprecipitation .........................................................75 
   6 
4.2.5 Immunofluorescence ............................................................................................75 
4.3 Results ......................................................................................................................76 
4.3.1 Direct sequence analysis of patient samples ........................................................76 
4.3.2 Mutant pro-vasopressin is retained .......................................................................78 
4.3.3 Localization of mutant pro-vasopressin.................................................................79 
4.4 Discussion ................................................................................................................80 
5 General Discussion .......................................................................................... 85 
5.1 Aggregation of mutant pro-vasopressin .....................................................................85 
5.2 The vasopressin domain of the precursor is necessary for aggregation but not 
oligomerisation ..........................................................................................................87 
5.3 Aggregation of mutant vasopressin precursors: a premature physiological event? ....88 
 Summary  7 
 
Summary 
Diabetes insipidus is a disregulation of water homeostasis characterized by large 
fluid turnover in the kidney. Water homeostasis is regulated by the hormone 
vasopressin by increasing reapsorption of water in the renal collecting duct. 
Autosomal dominant diabetes insipidus is caused by mutations in the precursor 
protein of vasopressin. More than 50 different such mutations are known. Mutant 
prohormones are retained within the cell and cause degeneration of vasopressinergic 
neurons in the hypothalamus by an unknown mechanism. 
In this work we identified three novel dominant mutations of the pro-vasopressin 
gene. We further show that different mutations in the precursor lead to the formation 
of disulfide-linked homo-oligomers and large aggregates with fibrillar morphology in 
the endoplasmic reticulum of transfected cultured cells, both fibroblasts and neuronal. 
In addition, bacterially expressed and purified pro-vasopressin spontaneously formed 
fibrils in vitro under oxidizing conditions. Further mutagenesis experiments showed 
that the presence of cysteines, but no specific single cysteine, is essential for 
disulfide oligomerization and aggregation in vivo. Our findings place autosomal 
dominant neurohypophyseal diabetes insipidus in the class of neurodegenerative 
diseases associated with amyloid-like protein aggregations. 
To identify the sequence responsible for aggregation, segments comprising ten 
amino acids throughout the precursor were replaced by a sequence composed 
almost entirely of prolines and glycines. Prolines and glycines have been shown to 
disrupt the formation of amyloids. Formation of large aggregates required the intact 
N-terminal ten amino acids. Disulfide-linked oligomers, however, were not abolished. 
These results indicate that the vasopressin moiety is essential for precursor 
aggregation and that disulfide-linked oligomers not necessarily lead to the formation 
of large aggregates. 
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1 General Introduction 
1.1 Water homeostasis 
For a living organism, stability of the composition and the volume of body fluids is 
critical to survival and function. This stability of the internal environment is known as 
homeostasis. Relatively small changes in physiologically important variables 
activate a series of feedback mechanisms which sets off events that will promptly 
restore the altered variable to the normal level. In water balance, homeostasis can 
be maintained despite large variations in water intake and loss. The largest part of 
this loss of water is due to urination, which is dependent on the kidney activity. 90% 
of the primary kidney filtrate is held back by the proximal compartments of the 
nephron, the remaining 10% is absorbed in the distal collecting tubules where water 
reabsorption is controlled by the antidiuretic hormone (ADH). 
The antidiuretic hormone of humans and most other mammals is vasopressin. Its 
synthesis occurs by the magnocellular neurons of the supraoptic and paraventricular 
nuclei of the hypothalamus from where it is transported to the neurohypophysis. 
Vasopressin secretion is regulated primarily by plasma osmolality, which is 
monitored by osmolality receptors located in the hypothalamus. These receptors are 
not very well characterized and react on hypovolemia and/or hypernatremia by 
releasing vasopressin to the blood stream. 
In the kidney, vasopressin from the bloodstream binds primarily to the vasopressin 
receptor V2 (V2R) at the basolateral side of the epithelial cells in the collecting duct 
(Fig 1). As a G-protein coupled receptor, it induces nucleotide exchange in G-
proteins at Gα. Gα-GTP activates adenylate cyclase thus generating elevated 
cAMP levels. This leads to subsequent phosphorylation of the water channel 
aquaporin 2 (AQP2) at its cytoplasmic C-terminus by protein kinase A. As a 
consequence, transport vesicles containing AQP2 fuse with the apical plasma 
membrane. The resulting channels permit increased water reabsorption from the 
renal collecting ducts. Through AQP3 and AQP4 channels at the basolateral side, 
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water molecules can leave the cell again into the bloodstream. If vasopressin levels 
decrease, AQP2 is reinternalized (Fig 1) (Levin 2001; Rutishauser & Kopp 1999). 
 
 
Fig 1 Vasopressin binds to its receptor and activates protein kinase A (PKA) which  induces fusion of 
aquaporin 2 containing vesicles with the plasma membrane. Water reapsorption persists as long as 
vasopressin remains bound to its receptor. (Rutishauser & Kopp 1999). 
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1.2 Diabetes insipidus 
If the concentration of the urine in the kidneys fails, polyuria and polydipsia are the 
consequence. This clinical condition is known as diabetes insipidus (DI). DI is 
characterized by excretion of abnormally large volumes (>30 ml/kg body weight/d 
for adults) of dilute urine. Three basic mechanisms are known to be the cause for 
DI. Firstly, absence of vasopressin from the blood due to a deficiency in the 
vasopressin production is referred to as neurohypophyseal diabetes insipidus. 
Secondly, renal resistance due to injury of the nephron or mutations in the 
vasopressin receptor is the cause for nephrogenic diabetes insipidus. Nephrogenic 
DI can be either an acquired disorder due to hypokalemia, hypercalcemia, or drugs 
(with lithium being the most notable example), or of hereditary origin. Almost 90% of 
hereditary nephrogenic DI disorders are due to mutations in the vasopressin 
receptor-2 gene (V2R), which causes a disease with X-linked recessive inheritance 
(XNDI or DIN type 1) (Morello & Bichet 2001). Furthermore mutations in AQP2 can 
also lead to DI. These mutations can be inherited in a dominant or recessive 
manner. Dominant AQP2 mutants are retained in the Golgi compartment. Since 
AQPs are thought to tetramerize, the retention of mutant AQP2 together with wild-
type AQP2 in mixed tetramers in the Golgi compartment is a likely explanation for 
the dominant inheritance of DI in this patients (Mulders et al. 1998). In a third 
mechanism, vasopressin can be suppressed by excessive water uptake without 
need. This condition is referred to as dipsogenic diabetes insipidus and is most 
often caused by an abnormality in the part of the brain that regulates thirst. 
Diagnosis of all kinds of DI takes place via a water deprivation test. Patients go 
through a defined period of water deprivation during which osmolality of the plasma 
and urine are measured and compared to each other. Assessment of the response 
to exogenous vasopressin can provide information on the DI subtype. 
 
1.2.1 Neurohypophyseal diabetes insipidus 
Limited capacity to secrete vasopressin during dehydration can be due to mutations 
in the pro-vasopressin gene. During the last decade a great diversity of peptide 
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producing neurons has been described in the brain and in the peripheral nervous 
system representing the so called peptidergic neurons. These are a group of 
interneurons which contain and secrete peptide hormones such as enkephalins, 
somatostatins, oxytocin and vasopressin. A major site of secretion for this type of 
hormones is the pituitary gland which consists of three different parts, the anterior, 
intermediate and the posterior lobe (Table 1). The posterior lobe is characterized by 
an enrichment of neuronal processes, essentially axons, and their terminals, 
comprising about 42% of the total volume. These processes are derived from 
magnocellular neurons located in the supraoptic and paraventricular nuclei of the 
hypothalamus. The secretory products of this type of neurons are stored in 
neurosecretory granules at the nerve terminals in the posterior pituitary and are 
released from there into the blood stream. 
Table 1: Pituitary hormones and their major targets and physiologic effect 
 Hormone Major target 
organ(s) 
Major physiological effects 
Anterior 
Pituitary 
Growth hormone Liver,  
adipose tissue 
Promotes growth (indirectly),  
control of protein,  










Stimulates secretion of 
glucocorticoids 
Prolactin Mammary gland Milk production 
Luteinizing hormone Ovary and testis Control of reproductive function 
Follicle stimulating 
hormone 
Ovary and testis Control of reproductive function 
Intermediate 
Pituitary 
Melanotropin Melanocytes Melanin synthesis 
Posterior 
Pituitary 
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1.2.2 Vasopressin precursor 
 
Fig 2: Gene structure and spliced precursor of vasopressin 
Vasopressin is a nonapeptide synthesized as a preprohormone. It possesses a 19 
amino acid signal sequence and a 93 amino acid carrier protein, the neurophysine II 
(NPII), followed by a glycopeptide of 39 amino acids, also referred to as copeptide, 
comprising a single N-linked glycosylation site. The gene encoding the precursor is 
located on chromosome 20p13 and consists of three exons (Fig 2) 
Vasopressin and oxytocin are quite similar in their structure. The genes encoding 
vasopressin and oxytocin are in a tandem array on chromosome 20, separated by 8 
Kb of DNA. The structure of oxytocin differs from that of vasopressin by only 2 
amino acids: Ile for Phe at position 3, and Leu for Arg at position 8. This close 
structural relationship suggests that both derive from a common ancestral gene. 
Mutation in the vasopressin gene can cause autosomal dominant 
neurohypophyseal diabetes insipidus. There are no hotspots for mutations 
responsible for the dominance. More than 50 mutations spread all over the 
precursor with exception of the glycopeptide are known and only one recessive 
mutation has been discovered so far in humans (Willcutts, Felner & White 1999). 
This exception results from reduced binding affinity to the vasopressin receptor in 
the collecting duct. 
Interestingly, most mutations in the vasopressin gene have a dominant phenotype. 
This type of DI is referred to as autosomal dominant neurohypophyseal diabetes 
insipidus (ADNDI). ADNDI usually has a delayed onset. The first symptoms appear 
during the first months and years of life. The mechanism by which mutations in the 
vasopressin gene can cause dominant DI despite the presence of a functional wild-
type allele, may be due to magnocellular cell death caused by an accumulation of 
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mutant hormone precursor in the endoplasmic reticulum. Death of magnocellular 
neurons could also explain the delayed onset of the disease since in early life 
enough vasopressin producing cells are present. 
 
1.2.3 ER retention of mutant vasopressin precursors 
The vasopressin precursor is cotranslationally targeted to the endoplasmic 
reticulum (ER). After entering the ER, the signal is cleaved off by signal peptidase. 
Upon translocation of the precursor, folding occurs, where chaperones play an 
important role of assisting in the folding process.  
The folded precursor forms a dimer. Dimerization is stabilized by binding of 
vasopressin into its binding pocket of the folded NPII (de Bree & Burbach 1998). 
The copeptide is modified at the Asp at position 5, where a glycan is attached. In 
the Golgi the glycan is further modified. Reaching the trans Golgi network (TGN) the 
prohormone is sorted into the regulated secretory pathway. Immature secretory 
granules bud off from the TGN. During maturation, prohormone convertase I 
cleaves the prohormone between the vasopressin peptide and NPII. Mature 
secretory granules containing processed vasopressin move along the axon from the 
cell periphery and are stored near the synapse prepared for regulated release. 
The effects of the DI mutations in the precursor have been studied by several 
groups using heterologous expression systems. Olias et al. (1996) showed that 
expression of the wilde-type and a mutant (G17V) in the pituitary cell line AtT-20 
exhibit distinct differences in processing and secretion of the molecules. The 
precursor of the wild-type was correctly glycosylated and processed. However, the 
mutant precursor, allthough core glycosylated remained endoglycosidase H 
sensitive. This indicated that the protein never reached the TGN. This was 
supported by the fact that the G17V mutant protein was restricted to the ER, in 
contrast to cells expressing the wild-type, where NPII was concentrated in the tips, 
as shown by immunofluorescence. 
The G227 mutation leading to a truncated signal peptide was shown to be 
glycosylated (Beuret et al. 1999), suggesting the truncated signal to be sufficient for 
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ER import. The fact that most of the precursor showed a higher molecular weight 
suggested failure in signal peptide cleavage. Secretion was drastically reduced and 
the protein was completely retained inside the ER. This was supported by co-
staining for the ER resident protein p63. 
Another signal peptide mutant A(-1)T examined by Siggaard et al. (1999) in 
Neuro2a cells showed an eight-fold reduction in secretion when compared to the 
wild-type. This precursor was also shown to be retained in the ER by the co-
localization with glucose-regulated protein 78 (GRP78). 
To elucidate the mechanism of ADNDI, Nijenhuis et al. (1999) studied five mutants, 
G14R, E47, E47G, G57S and G65V by stably expressing them in the 
neuroendocrine cell lines Neuro2a and PC12/PC2. All of the five mutants examined 
showed impairment of secretion, but to different extents. Retention of the precursors 
in the ER was indicated by sensitivity to endoglycosidase H and co-staining with the 
ER marker protein disulfide isomerase (PDI). 
The same results were obtained for the E87X mutant in PC12/PC2 and AtT-20 cells 
(Nijenhuis, Zalm & Burbach 2000), and the C85G mutant in PC12/PC2 (Nijenhuis et 
al. 2001), where reduced processing and secretion as well as co-localization with 
PDI were observed. The high level of expression of the mutant pro-hormone caused 
strong accumulation in the ER subsequently leading to enlarged ER sub-
compartments. 
These morphological changes of the ER could be evidence for severe disturbance 
and dysfunction of the ER which in turn could be responsible for dominance (Aridor 
& Hannan 2000; Aridor & Hannan 2002; Rutishauser & Spiess 2002). 
Since the phenotype is not linked to a specific site, any change in the amino acid 
sequence seems to be sufficient to induce misfolding and thus leads to retention. 
This retention, although variable between different mutations (Nijenhuis, Zalm & 
Burbach 1999), seems to be a hallmark for ADNDI and thus critical for 
pathogenesis. ADNDI is hence a trafficking defect. In order to understand this 
defect, comprehension of trafficking and thus the secretory pathway is crucial. 
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1.3 The secretory pathway  
1.3.1 ER entry 
If a protein is destined for secretion it is targeted to the ER, where it is, in the case 
of a mammalian cell, inserted into the lumen via a co-translational process. The 
endoplasmic reticulum consists of a netlike labyrinth of branching tubules and 
flattened sacs and is extended throughout the cytosol. The highly convoluted space 
within the tubules and sacs is called the ER lumen. The ER captures two types of 
proteins from the cytosol as they are being synthesized. Transmembrane proteins 
are only partly translocated across the ER membrane and are finally embedded in 
it. Water soluble proteins are fully translocated across the ER membrane, and 
released into the ER lumen. To ensure the direction of these proteins to the ER 
membrane, both kinds of protein possess the same kind of signal sequence which 
exhibits a stretch of hydrophobic amino acids. As these amino acids emerge from 
the ribosome, they are recognized and bound by the signal recognition particle 
(SRP). Translation is attenuated by binding of the signal sequence to SRP, and tight 
binding of SRP to its receptor targets the nascent peptide chain to the ER. The 
polypeptide chain enters the ER lumen via a gated channel. This channel is formed 
by the heterotrimeric Sec61 αβγ complex. On the luminal side of the ER membrane, 
the signal is cleaved by a signal peptidase. Entry is dependent on additional 
components. Requirement of translocating chain-associated membrane protein 
(TRAM) has been shown in reconstitution experiments in lipid vesicles (Görlich & 
Rapoport 1993). 
During translocation, proteins are also glycosylated on specific aspargine residues 
(N-linked glycosylation). Oligosaccharide units consisting of 14 sugar residues are 
added to acceptor asparagine residues of growing polypeptide chains as they are 
translocated into the ER. 
 
1.3.2 Quality control 
There are distinct biophysical features, distinguishing native from non-native 
conformation. These differences like exposed hydrophobic regions, unpaired 
 General Introduction  16 
cysteines and the tendency to aggregate are the basis for primary quality control. 
Before newly synthesized polypeptides reach their final destinations, they may 
undergo five principal modifications: Formation of disulfide bonds, proper folding, 
addition and processing of carbohydrates, specific proteolytic cleavages, and 
assembly into multimeric proteins. Essential for normal structure and activity in 
proteins that contain more than one disulfide bond is the proper pairing of cysteine 
residues. The reorganization of disulfide bonds is accelerated by the enzyme 
protein disulfide isomerase (PDI). 
Important molecular chaperones and folding sensors used in the primary quality 
control are abundant in the ER. BiP, calnexin, calreticulin, glucose-regulated protein 
94 (GRP94) and the thiol-disulfide oxidoreductases protein disulphide isomerase 
(PDI) and ERp57 are part of this group. Important for the folding of glycoproteins is 
the calnexin/calreticulin cycle. During synthesis of glycoproteins with N-glycans, the 
oligosaccharide Glc3Man9GlcNAc2 is attached to the asparagine residue in the 
consensus sequence NXS/T (X≠P) of newly synthesized proteins in the ER. Two 
glucoses are removed by glucosidase I and II. By this step a monoglucosylated 
(Glc1Man9GlcNAc2) glycoprotein is generated, which can interact with calnexin and 
calreticulin. Both chaperones are associated with the thiol-disulfide oxidoreductase 
ERp57 through an extended arm-like domain. During disulfide-bond formation, 
ERp57 forms interchain disulfide bonds (S-S) with bound glycoproteins. The 
decision about retention or release from the control cycle is made by two 
independent enzymes. The terminal glucose is removed by glucosidase II. This 
permits dissociation of the glycoprotein from the respective lectin. If folding fails, the 
glycoprotein becomes substrate for UDP-glucose:glycoprotein glucosyltransferase 
(UGGT), which reattaches a terminal glucose, and thus causes the proteins to 
reassociate with the lectin. Patches of hydrophobic amino acids are suggested to be 
the recognition motif for reglucosylation (Caramelo et al. 2003). 
If the protein permanently fails to fold, ERα1,2-mannosidase I removes a mannose 
from the middle branch of the oligosaccharide. This is the recognition pattern for the 
ER degradation-enhancing 1,2-mannosidase-like protein (EDEM), which is probably 
responsible for the targeting of glycoproteins for ER-associated degradation 
(ERAD). Only If the folding deficiency is final after multiple cycles of deglucosylation 
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and reglucosylation the proteins are removed from the calnexin/calreticulin cycle 
and eliminated (Molinari et al. 2003). 
 
1.3.3  ER associated degradation (ERAD) 
It is not surprising that protein misfolding can lead to a multitude of diseases, such 
as cystic fibrosis, antitrypsin deficiency and protein aggregation diseases, such as 
Huntington‘s, Parkinson‘s, Alzheimer‘s and prion-associated diseases. To prevent 
misfolding-induced toxicity, aberrant proteins are often destroyed. If folding is 
delayed, or an illegitimate conformation arises, the substrate is either subjected to 
additional folding cycles (see 1.3.2) or is selected for a process termed ER-
associated degradation (ERAD). ERAD involves a large number of components, 
which have been identified through both genetic and biochemical approaches 
(Sayeed & Ng 2005; Hebert & Molinari 2007; Nakatsukasa & Brodsky 2008). These 
efforts revealed that ERAD substrates are recognized, targeted, retrotranslocated, 
polyubiquitylated, and then degraded by the 26S proteasome (Fig 3). Individual 
components have been found to catalyze unique steps during ERAD. Most of these 
components are conserved from yeast to humans. 
 
Fig 3: The ERAD pathway (Vembar & Brodsky 2008) 
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The first step of the ERAD pathway is the recognition of the substrate. Proteins, 
including soluble and integral proteins, polypeptides which have failed to become 
post-translationally modified or are otherwise damaged or misfolded, and 
unassembled members of multiprotein complexes are potential ERAD substrates. It 
is not quite clear how ERAD substrates are distinguished from proteins that are 
properly folded or that are on the correct folding pathway, probably many proteins 
are mistakenly targeted for ERAD. Misfolded proteins are recognized by 
cytoplasmic and luminal chaperones and associated factors, such as 70 kDa heat-
shock protein (Hsp70)-family members, calnexin and calreticulin, and PDI. In a next 
step ERAD substrates are targeted to the retrotranslocation machinery (the 
retrotranslocon) and/or to E3 ligases. Cell-division cycle-48 (Cdc48) complex and 
other components such as molecular chaperones or the proteasome initiate the 
substrate retrotranslocation into the cytoplasm. In a subsequent step, ubiquitylation 
by E3 ubiquitin ligases takes place, as proteins exit the retrotranslocon. This 
promotes further retrotranslocation and is assisted by cytoplasmic ubiquitin-binding 
protein complexes. The receptor of 19S cap of the 26S proteasome recognized 
polyubiquitylated substrate, once displaced into the cytoplasm, and the polyubiquitin 
tag is removed by de-ubiquitylating enzymes. The substrate is then inserted into the 
20S catalytic core of the proteasome, where it is broken up into peptide fragments. 
The ubiquitin generated by this process can be recycled for subsequent rounds of 
modification (Vembar & Brodsky 2008). 
 
1.3.4 ER Stress 
The ER stress response is an important adaptive cellular signaling response. It aims 
to maintain the balance between secretory protein synthesis in the ER against 
protein folding capacity. If an imbalance occurs between these 2 factors, the ER 
stress response, also known as the unfolded protein response (UPR), is activated. 
The UPR consists of different pathways which in the end, aim to restore ER 
homeostasis by down-regulating global protein translation, increasing the ER folding 
capacity by up-regulating ER chaperones, and the degradation of misfolded 
proteins. It has been estimated that approximately 30% of all newly synthesized 
proteins are rapidly degraded, possibly as a result of improper folding (Schubert et 
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al. 2000). In mammalian cells, the UPR may also activate genes and pathways that 
are not directly linked to the expression of resident ER proteins. For example, 
treatment of cells with the glycosylation inhibitor tunicamycin, a potent inducer of the 
UPR, leads to the induction of growth arrest and programmed cell death in many 
cell types (Larsson, Carlberg & Zetterberg 1993; Pérez-Sala & Mollinedo 1995; 
Carlberg et al. 1996). 
A build up of misfolded protein would impose a major problem for the cell, such 
accumulations can lead to perturbations in the ER environment, such as alterations 
in redox state or calcium levels. In response to ER stress, 3 ER localized 
transmembrane signal transducers are activated (Tirasophon, Welihinda & Kaufman 
1998) (Fig 4). These transducers are inositol requiring kinase 1 (IRE1), double-
stranded RNA-activated protein kinase-like ER kinase (PERK) and the activating 
transcription factor 6 (ATF6). All three inducers of ER stress response are inactive 
as long as they are bound to the ER chaperone BiP. 
 
Fig 4: ER stress pathway (Cnop et al. 2008) 
Activated IRE1 leads to alternative splicing of XBP1, which is an inducer of genes 
involved in ER expansion, protein folding and the degradation of misfolded protein. 
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The IRE1 gene was duplicated in mammals, in contrast to yeast. This duplication 
gave rise to IRE1α and IRE1β. Whereas IRE1α is expressed in all mammalian cells, 
IREβ is primarily expressed in epithelial cells (Tirasophon, Welihinda & Kaufman 
1998; Wang et al. 1998; Bertolotti et al. 2001). The two isoforms seem to have the 
same in vitro activities, subcellular localization and downstream target (XBP1 
mRNA). However, whereas IREα is essential for mammalian development (Zhang 
et al. 2005), IRE1β deletion does not lead to significant defects (Bertolotti et al. 
2001). 
Activated ATF6 is exported to the Golgi apparatus. There it is cleaved from the 
membrane. This free form translocates to the nucleus, where it induces the 
transcription of ER chaperones such as BiP. 
PERK in its activated form phosphorylates eIF2α and thereby prevents ternary 
complex formation and suppresses global translation initiation. Activation of eIF2α 
facilitates translation of proteins like ATF4 which in turn activates the 
CCAAT/enhancer binding protein (C/EBP) homologous transcription factor (CHOP), 
the Bcl-2 family members (Bak/Bax), caspase-12, and c-Jun NH2-terminal kinase 
(JNK) are induced. JNK and caspase-12 induce growth arrest and DNA damage-
inducible protein (GADD34), which associates with protein phosphatase 1 (PP-1) 
and dephosphorylates eIF2α, acting as a negative feedback loop. Consequences of 
the UPR are either reconstitution of normal function or apoptosis. 
 
1.3.5 ER export and ERGIC 
A properly folded, and thus functional protein is packed into vesicles covered by 
cytosolic coat protein II (COPII) and transported out of the ER to the Golgi. The coat 
proteins form a shell around the forming vesicle, shaping it into a transport vesicle 
(Bonifacino & Lippincott-Schwartz 2003) destined for the cis Golgi. The COPII coat 
consists of five subunits: Sar1, Sec23, Sec24 and Sec13, Sec31. Sar1 is a small 
GTPase that inserts its N-terminal amphipathic helix into the cytoplasmic leaflet of 
the ER membrane bilayer when bound to GTP. Sec12 serves as the guanine-
nucleotide exchange-factor (GEF) for Sar. Sar1 recruits Sec23 and Sec24, which 
form a tightly associated heterodimeric complex, and bind directly to the ER 
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membrane, forming an inner coat. The Sar1-Sec23-Sec24 complex recruits the 
heterotetrameric Sec13-Sec31 complex which builds the outer coat. This outer coat 
is not in direct contact with the ER membrane surface. Cargo proteins are primarily 
selected by Sec24 to be incorporated into COPII vesicles via binding to the 
cytoplasmic domains of ER transmembrane proteins destined for anterograde 
compartments. Sar1 and Sec23 are also known to bind cargo molecules, but their 
role in discrimination of COPII cargo versus ER-resident proteins is less clear. 
Sec23 is a GTP-activating protein (GAP) for Sar1, its activity is stimulated by 
binding of the outer coat. If the coat is completely polymerized, hydrolysis of Sar1-
bound GTP to GDP occurs, which leads to the depolymerization of the coat, and the 
vesicle is uncoated, so that the COPII subunits can be recycled for another round of 
vesicle formation. 
The ER-derived COPII vesicles fuse with each other or with a target compartment, 
to transport cargo to the next station (Beckers et al. 1989; Kaiser & Schekman 
1990; Rexach & Schekman 1991). In yeast and higher eukaryotes the ER to Golgi 
transport is restricted to specialized, long-lived subdomains of the ER, the ER-exit 
sites (ERES) (Bannykh, Rowe & Balch 1996; Hammond & Glick 2000).In yeast, 
fusion occurs directly with the cis-Golgi whereas in higher eukaryotes ER to Golgi 
transport is directed via the tubulovesicular membrane clusters of the ER-Golgi 
intermediate compartment (ERGIC), the marker of which is the lectin ERGIC-53 
(Hauri et al. 2000; Schweizer et al. 1988). ERGIC constitutes an independent 
structure, that is not continuous with the ER or the cis-Golgi (Sesso et al. 1994; 
Bannykh, Rowe & Balch 1996; Fan, Roth & Zuber 2003; Klumperman et al. 1998). 
The ERGIC serves as the first post ER sorting station for anterograde and 
retrograde protein traffic. (Appenzeller et al. 1999; Aridor et al. 1995; Ben-Tekaya et 
al. 2005). This sorting functions via transport signals such as KDEL in soluble 
proteins in retrograde transport. KDEL binds to the KDEL receptor, which in turn, is 
recognized by COPI. About the anterograde transport little is known. Like in ER 
export, anterograde exit from the ERGIC might be signal mediated or occur by 
default. Successful anterograde delivery from the ERGIC to the Golgi requires 
dissociation of cargo proteins from their receptors in the ERGIC. This suggests, that 
the ERGIC exhibit different features, compared with the ER, where cargo-receptor 
interaction occurs. pH has been shown to be one of these features. Acidification of 
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cells in culture inhibits the association of ERGIC-53 with its cargo procathepsin Z, 
and neutralization of organelle pH by chloroquine specifically impairs the 
dissociation of this glycoprotein in the ERGIC (Appenzeller-Herzog et al. 2004). The 
lumen of the ER has been shown to be neutral (pH 7.4) (Wu et al. 2001), the 
ERGIC however, is the earliest low-pH site in the secretory pathway. Its exact pH is 
unknown, but it is unlikely to be lower than that of the TGN (pH 6.4) (Machen et al. 
2003). Only slight reduction in pH compared to the pH of the ER would be sufficient 
to act as a general trigger for the dissociation of cargo-receptor complexes in 
combination with other factors, such as calcium concentrations. 
 
1.3.6 Intra Golgi transport 
The central sorting and processing station of the secretory pathway is the Golgi 
apparatus. It is composed of 4 to 6 flat cisternae, which are arranged into several 
stacks, linked by tubular connections. Within these stacks, it is ensured, that cargo 
proteins, synthesized in the ER are modified and packaged into carriers for 
transport to their final destination. Post-translational modifications of secretory cargo 
proteins are assured by processing enzymes, such as glycosidases and 
glycosyltransferases. Thus, forward cargo movement must be coordinated with an 
assembly line of processing enzymes that sequentially modify the cargo proteins 
(Dean 1999; Helenius & Aebi 2001; Lowe & Marth 2003; Opat, van Vliet & Gleeson 
2001). 
Two models for the movement of cargo through the Golgi have been proposed. 
Important for both models is coatomer protein complex I (COPI). COPI-coated 
vesicles are positioned laterally from the Golgi cisternae. According to the vesicular 
transport model, the Golgi is a relatively static structure. The molecules are 
transported through the cisternae in sequence, carried by specific COPI transport 
vesicle (Rothman & Wieland 1996). COPI vesicles carry cargo and move in an 
anterograde fashion from one Golgi cisterna to the next (Ostermann et al. 1993; 
Rothman 1994). In the cisternal maturation model, however, the Golgi is viewed as 
a dynamic structure. The cisternae themselves move through the Golgi stack (Glick 
& Malhotra 1998; Matsuura-Tokita et al. 2006). At the cis-Golgi new cisternae would 
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assemble and old cisternae would disassemble at the trans-Golgi. Transport of 
resident enzymes from the more trans side to the more cis side would be achieved 
via COPI coated vesicles. The characteristic distribution of Golgi enzymes is 
explained by retrograde flow. the COPI vesicles move in a retrograde fashion and 
function as a retrieving device that is used by Golgi enzymes to maintain their 
specific and differential localization over the Golgi stack (Glick, Elston & Oster 1997; 
Pelham 1998). The two models are not mutually exclusive. Transport may occur by 
a combination of both models. 
COPI coat assembly begins with the membrane recruitment and activation of the 
small soluble GTPase Arf1. This is mediated by guanine nucleotide exchange 
factors (GEFs) that convert Arf1 to its active, GTP-bound form. Upon activation at 
the membrane, Arf1 recruits a coatomer complex from the cytoplasm. Coatomer 
bound to Arf1 then binds membrane-associated ArfGAP, the GTPase activating 
protein for Arf1. The complex of coatomer–Arf–ArfGAP polymerizes into a coat on 
the membrane, concentrating cargo proteins directly beneath it. The coat deforms 
the membrane into a bud. This bud pinches off the membrane as a coated vesicle. 
Disassembly of the coat occurs when ArfGAP hydrolyzes the GTP on Arf1. This 
releases Arf1 into the cytoplasm, which in turn triggers the release of coatomer and 
ArfGAP from the membrane. The components are then free to be reused for coat 
reassembly. 
 
1.3.7 Granule formation 
Endocrine and neuro-endocrine cells possess a regulated secretory pathway, in 
addition to the constitutive pathway present in all cells (Burgess & Kelly 1987). A 
hallmark of these cells are dense-core secretory granules which are responsible for 
regulated secretion of cargo molecules. Peptide hormones are synthesized as large 
precursors at the ER and transported to the Golgi apparatus. At the TGN, the 
precursors are packaged into secretory granules where they are processed to 
active peptides and secreted in a regulated manner in response to stimuli. The 
dense core of this granules consist of large insoluble secretory proteins and peptide 
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aggregates, that are formed by self-association (Dannies 2001; Arvan et al. 2002; 
Tooze 1998). 
There are two non-exclusive models proposed on how secretory granules are 
formed and how specific cargo selection is achieved. The first one, ―sorting for 
entry‖, is analogous to receptor-mediated endocytosis and mannose 6-phosphate 
receptor-dependent lysosomal transport (Schmid 1997). In this model cargo binds 
to receptors, which in turn recruit a cytosolic coat. The alternative model is termed 
"sorting-by-retention". Here it is proposed that selective aggregation of regulated 
cargo in the TGN results in an immature granule. Captured non-granule molecules 
are subsequently removed in vesicles budding from maturing secretory granules by 
clathrin-coated vesicles and by so-called constitutive-like secretion, whereas 
specific granule cargo is retained (Kuliawat & Arvan 1992). It has been proposed 
that a single protein of endocrine and neuronal cells, chromogranin A (CgA), 
controls secretory granule biogenesis (Kim et al. 2001). Expression of CgA was 
even found to induce granular structures in transfected CV-1 fibroblast cells. It has 
been shown that several other cargo proteins of the regulated secretory pathway of 
endocrine cells, peptide hormone precursors as well as granins, induce the 
formation of granule-like structures when expressed in cell lines normally lacking 
regulated secretion. It has also been shown that expression of cargo is sufficient to 
drive segregation of regulated and constitutive secretory proteins and the formation 
of dense membrane-bound accumulations. These accumulations showed a similar 
ultrastructural appearance as secretory granules, suggesting that initial granule 
formation requires no additional machinery specific to regulated secretory cells. The 
regulated cargo itself is sufficient (Beuret et al. 2004). 
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Fig 5: Biogenesis of secretory granules in neuroendocrine cells. Step (1) Regulated secretory 
proteins (RSPs; green spheres with curly tail) become associated with a specialized region of the 
TGN and (filled green circle with stalk). (2) Additional components, including SNARE molecules (blue 
and red ‗§‘), other soluble non-secretory granule proteins, or cargo (yellow spheres) and non-
secretory granule membrane proteins (yellow triangles), are included into the nascent bud. (3) After 
formation, ISGs undergo homotypic fusion mediated by SNAREs, followed by membrane remodeling 
(4). Remodeling to the mature secretory granule (MSG). Abbreviation: EE, early endosome. (Tooze, 
Martens & Huttner 2001) 
 
1.4 Neurodegeneration 
A common cellular and molecular mechanism of neurodegenerative diseases, such 
as Alzheimer‘s, Huntington‘s and Parkinson‘s disease, is the formation of inclusion 
bodies and protein aggregations, which can be found in the cytoplasm, the nucleus 
or extracellularly. 
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The ability of proteins to fold into a structure, which is biologically active, is encoded 
in their amino acid sequence. Protein folding involves populations of transiently 
denatured, or partially folded intermediate structures that rapidly convert into the 
final native state. However, this optimal situation is often perturbed when the native 
fold is destabilized by mutation, or when changes occur in the cellular or 
physicochemical environment in which the polypeptide is produced or kept. 
Huntington‘s disease is a neurodegenerative disorder, caused by an abnormal 
polyglutamine (polyQ) expansion within the protein huntingtin (Htt). Individuals with 
more than 40 polyQ repeats will always develop the disease within a normal life 
span. A characteristic feature of Huntington‘s is the death of striatal and cortical 
neurons, paralleled by aggregation of Htt into microscopic intracellular deposits. 
These aggregations are located in the nucleus and the cytoplasm. Formation of 
these inclusions has been associated with neurodegeneration (Davies et al. 1997; 
Becher et al. 1998; DiFiglia et al. 1997; Ordway et al. 1997). However, other 
reported no correlation or even a negative one (Saudou et al. 1998; Taylor et al. 
2003; Shimohata et al. 2002). The correlation between inclusions and degeneration 
is thus not clear. 
In Alzheimer‘s disease (AD), massive degeneration of the brain mass occurs. Over 
twenty years ago, the amyloid hypothesis, explaining the neuropathology was 
proposed, but the molecular pathogenesis still needs to be clarified. The loss of 
cerebral substance is often accompanied by the formation of extracellular plaques, 
composed of amyloid beta (Aβ) peptide and intracellular fibrillary tangels composed 
of hyperphosphorylated tau protein. Genetic animal modeling and biochemical data 
have brought up the suggestion that Aβ plays an important role in Alzheimer‘s 
disease. Cleavage of the amyloid precursor protein (APP) by the action of two 
aspartyl proteases (β- and γ-secretase) leads to the formation of Aβ fragments 
(Haass et al. 1992; Seubert et al. 1992; Shoji et al. 1992). After cleavage of APP by 
β-secretase, a 99 amino acid long stub is left in the membrane, which is 
subsequently cleaved by the γ-secretase, which leads to the release of Aβ. Three 
principal forms (Aβ38, 40 or 42) of Aβ are produced, depending on the exact point 
of cleavage. The longer form Aβ 42 is far more prone to oligomerize and form 
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amyloid fibrils than the Aβ40 peptide (Burdick et al. 1992; Jarrett, Berger & 
Lansbury 1993). 
The familial form Parkinson‘s disease (PD) is caused by degeneration of 
dopaminergic neurons in the substancia nigra of the midbrain (Forno 1996). The 
pathological hallmark of adult-onset PD are Lewy bodies, inclusion bodies found in 
the cytoplasm of neurons, often near the nucleus. Lewy bodies contain large 
amounts of the protein α-synuclein. 
Amytrophic lateral scleorsis (ALS) is a disease caused by degeneration of lower 
motor neurons in the lateral horn of the spinal cord and upper motor neurons of the 
cerebral cortex (Cleveland & Rothstein 2001). One familial form, which is of early 
onset but relatively rare can be caused by mutations in the superoxide dismutase 
(SOD1) gene. A murin model, overexpressing mutant SOD1, showed cytoplasmic 
inclusions, containing aggregated SOD1 protein (Bruijn et al. 1998; Rakhit et al. 
2002). 
Prions are exceptional infectious pathogens that cause a group of invariably fatal 
neurodegenerative diseases, mediated by an entirely novel mechanism. Prion 
diseases occur as genetic, infectious, or sporadic disorders, all of which involve 
misfolding of the prion protein (PrP), a constituent of normal mammalian cells 
(Prusiner 1991). Bovine spongiform encephalopathy (BSE), scrapie found in sheep, 
and Creutzfeldt–Jakob disease (CJD) of humans are among the most notable prion 
diseases. Prion disease is a prototypical protein conformation disease, where 
cellular PrP (PrPC) is converted into PrPSc through a posttranslational process, 
during which it acquires a high β-sheet content (Pan et al. 1993). This leads to the 
formation of amyloid plaques appearing similar to those of AD. 
It is likely that the formation of these various aggregates constitute an end-stage 
manifestation of a multistep process. The role of these aggregation in toxicity has 
been a matter of great controversy, although many lines of indirect evidence link 
aggregation to toxicity. However, it has been shown that inclusion bodies and other 
visible aggregates correlate poorly with the severity of neurodegenerative diseases 
such as Alzheimer‘s (Terry et al. 1991) or Parkinson‘s (Tompkins & Hill 1997). It has 
also been shown that cells expressing comparable levels of the huntingtin fragment, 
were less likely to die if they formed inclusion bodies (Arrasate et al. 2004). These 
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observations raise the question whether the formation of inclusion bodies and 
visible protein aggregations are protective, and even represent a cellular and 
molecular mechanism to deal with aggregated and misfolded proteins. 
Proteins always have a certain tendency to aggregate. This forced the cell to evolve 
mechanisms to deal with misfolded or abnormal proteins. Molecular chaperones are 
able to provide the first line of defense against protein aggregation. The function of 
these molecules is to assist in folding of newly synthesized proteins and refold them 
if necessary which renders them non-toxic (section 1.3.2). A further defense 
mechanism lies in the function of the proteasome which degrades non functional 
proteins in the cytoplasm and the nucleus. Autophagy constitutes another way of 
dealing with wrongly synthesized proteins and aggregates. 
As a last resort aggregates can be sequestered by microtubule-mediated transport 
and concentrated at a special cytoplasmic site next to the centriole. These 
accumulations of aggregated material, usually rather big in size and thus visible by 
light microscopy, are called aggresomes. They are likely to constitute an end 
product of an active process to cope with misfolded proteins. 
There is evidence that aggregates might be a protective response of the cell against 
misfolded proteins. However, there is also evidence that the aggregation process 
itself is likely to be related to toxicity in neurodegeneration, and that there may be 
common mechanisms of toxicity among the described neurodegenerative diseases. 
 
1.5 Neurotoxicity in ADNDI 
As already mentioned in section 1.3.2, misfolded proteins are usually degraded via 
the ubiquitin-proteasome pathway. Having this in mind, one would expect all the 
listed mutations in the vasopressin gene to be recessive, since they are all likely to 
be misfolded. Friberg et al. (2004) showed, that the mutants are retrotranslocated to 
the cytosol and degraded by the proteasome. Most of the cases are heterozygous 
for these mutations thus the correct allele of the gene is still present and one would 
expect to find fully functional vasopressin in circulation. However, all listed 
neurohypophyseal diabetes insipidus mutations are dominant. There is only one 
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recessive mutation known in humans. The resulting hormone has a low affinity for 
its receptor in the kidney and is thus to be seen as a null mutation. The mechanism 
of this dominance has currently not been determined. Ito et al. (1999) proposed a 
model in which vasopressin precursors form heterodimers with wild-type products to 
alter their function, and contribute to the pathogenesis of ADNDI. They examined 
the physical and functional interactions between wild-type and mutant vasopressin 
precursors, by expressing epitope-tagged precursors in cultured cells. Crosslinking 
experiments showed, that wild-type and mutant precursors were able to build homo- 
and hetero-dimers, and that mutant precursors inhibited the trafficking of the wild-
type protein from the ER to the Golgi apparatus. According to this hypothesis, the 
secretion of vasopressin would be decreased. However, the cell would still be able 
to adapt to increasing demands of hormone by increasing the expression of 
vasopressin and the phenotype would thus still be a recessive one. 
Another hypothesis to explain the phenomenon comes from clinical data from 
individuals affected by diabetes insipidus. Studies in patients revealed low levels of 
circulating vasopressin accompanied by gliosis and hypocellularity of 
vasopressinergic neurons in the hypothalamus (Hanhart 1940; Braverman, Mancini 
& McGoldrick 1965; Gaupp 1941; Bergeron et al. 1991). Blotner (1958) suggested 
that hereditary diabetes insipidus represents a selective neural system 
degeneration. Taken all together, this supports the hypothesis that vasopressin 
mutants exert a toxic effect on their host cells which in turn would be an explanation 
for the dominant inheritance. The nature of this cytotoxic effect of mutant pro-
vasopressin is still not explained and needs further investigation. 
Heterologous expression studies delivered more support for the cytotoxicity 
hypothesis. Neuro2a cells, stably expressing the mutants A(-1)T, E47, G57S and 
C67X were not much affected in growth and viability. However, when valproic acid 
was used to initiate differentiation of the cell to a neuronal cell type, viability was 
significantly reduced. The reduction of viability differed between the different 
mutations (C67X>A(-1)T>G57S> E47) (Ito & Jameson 1997). 
Several animal models have been established to study ADNDI. The best-known 
mutation in rat is the Brattleboro mutation, where a deletion of a guanine at the 
position 65 of neurophysin causes a frameshift. This frameshift leads to a precursor 
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without a stop codon, and causes a read-through into the poly A tail. However, 
since the resulting protein is poorly expressed, the resulting phenotype is recessive 
and thus not directly comparable with the situation in ADNDI patients (Schmale et 
al. 1984). Si-Hoe et al. (2000) created a transgenic rat model expressing the C67X 
mutation. This mutation did not show a disease phenotype in rats. The mutant was 
retained in the ER. However, cell death or atrophy of magnocellular neurons could 
not be observed. In a subsequent study using the same transgenic rat strain, the 
authors showed autophagy to accompany accumulation of mutant precursor in the 
ER (Davies & Murphy 2002). Autophagy was claimed to act as a prosurvival 
mechanism in ADNDI since inhibition of autophagy decreased cell viability (Castino 
et al. 2005). 
Russel et al. (2003) showed in their work that knock-in mice expressing the C67X 
mutation revealed a clear ADNDI phenotype with polyuria and polydipsia worsening 
with age, in parallel with extensive loss of neurons in the supraoptic and 
paraventricular nuclei. Interestingly, the A(-1)T mutation did not cause any defects. 
In a recent publication a novel murine knock-in model expressing the mutant C67X 
was established. These heterozygous mice manifested progressive polyuria. Large 
inclusion bodies with gradually increasing size were present in the supraoptic 
nucleus (SON). The size of these inclusions developed in parallel with the increases 
in urine volume. Localization of these aggregates to the ER was shown by electron 
microscopy. However, counting cells expressing vasopressin mRNA in the SON 
indicated that polyuria had progressed substantially in the absence of neuronal loss 
(Hayashi et al. 2009). Taking these different studies together, the use of animal 
models seems to provide only contradictory information about whether cytotoxicity 
is the cause for ADNDI or not. Experiments in cell culture seemed to look more 
promising so up until now. 
 
1.6 Aim of this thesis 
Different experiments have shown that ADNDI is linked to a trafficking defect 
probably caused by misfolding of the mutant precursor. The mutant precursor was 
shown to be retained and formed disulfide-linked oligomers (Beuret et al. 1999; 
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Christensen et al. 2004; Friberg, Spiess & Rutishauser 2004; Ito & Jameson 1997; 
Nijenhuis, Zalm & Burbach 1999; Olias, Richter & Schmale 1996; Siggaard et al. 
1999). The role of these oligomers in terms of disease progression is still not clear. 
The aim of this thesis was to gain further insights into the mechanism causing 
ADNDI mutants to be dominant. Using a cell culture approach, we wanted to 
characterize the structural properties of the precursor leading to retention and inter 
protein disulfide formation. 
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2 Part I: Dominant pro-vasopressin mutants 
that cause diabetes insipidus form 
disulfide-linked fibrillar aggregates in the 
endoplasmic reticulum 
2.1 Summary 
Autosomal dominant neurohypophyseal diabetes insipidus results from mutations in 
the precursor protein of the antidiuretic hormone arginine vasopressin. Mutant 
prohormone is retained in the endoplasmic reticulum of vasopressinergic neurons 
and causes their progressive degeneration by an unknown mechanism. Here, we 
show that several dominant pro-vasopressin mutants form disulfide-linked homo-
oligomers and develop large aggregations visible by immunofluorescence and 
immunogold electron microscopy, both in a fibroblast and a neuronal cell line. 
Double-labeling showed the pro-vasopressin aggregates to colocalize with the 
chaperone calreticulin, indicating that they originated from the endoplasmic reticulum. 
The aggregates revealed a remarkable fibrillar substructure. Bacterially expressed 
and purified mutant pro-vasopressin spontaneously formed fibrils under oxidizing 
conditions. Mutagenesis experiments showed that the presence of cysteines, but no 
specific single cysteine, is essential for disulfide oligomerization and aggregation in 
vivo. Our findings assign autosomal dominant diabetes insipidus to the group of 




Familial neurohypophyseal diabetes insipidus, a disorder of water homeostasis, 
results from the lack of circulating antidiuretic hormone vasopressin, normally 
produced in vasopressinergic neurons in the hypothalamic magno- and parvocellular 
nuclei. As a consequence, vasopressin-mediated reabsorption of water from the 
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renal collecting ducts is deficient, causing patients to lose large amounts of 
unconcentrated urine and to suffer from increased thirst. The disease is caused by 
mutations in the gene encoding the vasopressin pre-pro-hormone. The vasopressin 
precursor consists of a signal peptide of 19 amino acids, the 9-amino acid hormone, 
a 3-amino acid linker, the 93-amino acid carrier protein neurophysin II (NPII), a single 
linker amino acid, and a C-terminal glycopeptide of 39 amino acids (Fig 6). The 
precursor is stabilized by the formation of 8 disulfide bridges, one in the hormone and 
seven in the NPII moiety. 
 
Fig 6: Wild-type and mutant vasopressin precursors. The domain organization of the vasopressin 
precursor (signal sequence in gray, vasopressin in green, NPII in blue, glycopeptide in yellow) is 
shown with cysteines as red dots, disulfide bridges as red lines, and the glycosylation site as a 
diamond. The positions of known ADNDI mutations are indicated as dots above the sequence (black 
for missense, pink for stop codon mutations). The only recessive mutation is indicated by a green dot. 
The mutations analyzed in this study are indicated by arrows. 
 
Over 50 pathogenic mutations of the human vasopressin gene have been reported 
that alter the signal peptide, the hormone, or the NPII moieties (Christensen & Rittig 
2006). So far, no mutations have been found in the glycopeptide. Almost all 
mutations are dominant. Only the P7L mutant (Pro7 of vasopressin mutated to Leu; 
(Willcutts, Felner & White 1999)) causes a recessive form of the disease. Autosomal 
dominant neurohypophyseal diabetes insipidus (ADNDI) shows a high penetrance 
with symptoms beginning weeks to months after birth. Postmortem histological 
studies of affected individuals have shown degeneration of the vasopressinergic 
magnocellular neurons (Bergeron et al. 1991; Braverman, Mancini & McGoldrick 
1965; Green, Buchan & Swanson 1967; Nagai et al. 1984). A knock-in mouse model 
expressing the human pathogenic mutant C67X (Cys67 of NPII mutated to a stop 
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codon) confirmed the neurotoxic effect of the mutant protein on vasopressinergic 
cells (Russell et al. 2003), but the mechanism causing cell death remains unknown. 
Expression studies have shown that dominant pro-vasopressin mutants are not 
secreted, but are retained in the endoplasmic reticulum (ER) (Beuret et al. 1999; 
Christensen et al. 2004; Friberg, Spiess & Rutishauser 2004; Ito & Jameson 1997; 
Nijenhuis, Zalm & Burbach 1999; Olias, Richter & Schmale 1996; Siggaard et al. 
1999). Most of the retained mutant protein is degraded by cytosolic proteasomes 
after retrotranslocation (Friberg, Spiess & Rutishauser 2004). Here, we show that 
newly synthesized mutant precursors form disulfide-linked homo-oligomers and large 
ER-derived accumulations with a fibrillar ultrastructural appearance. Fibril formation 
was reproduced by the purified precursor in vitro. The results suggest that disulfide-
linked oligomers in part escape degradation and gradually aggregate. Autosomal 
dominant diabetes insipidus thus belongs to the neurodegenerative diseases 
associated with fibrillar protein aggregation. 
 
2.3 Results 
2.3.1 Secretion-deficient dominant mutants form disulfide-linked homo-
oligomers 
To assay for secretion, wild-type pro-vasopressin, the recessive mutant P7L, and the 
dominant mutants ∆E47, Y2H, C28Y, and ∆G227 were expressed in COS-1 cells, 
pulse-labeled with [35S]methionine/cysteine, chased for 2 h, isolated from the cells 
and from the media by immunoprecipitation, and analyzed by SDS-gel 
electrophoresis and autoradiography (Fig 7A). As expected, a considerable fraction 
of the wild-type and of P7L was recovered from the media, reflecting their ability to 
fold and pass ER quality control. In contrast, the dominant mutants ∆E47, Y2H, and 
C28Y were completely retained in the cells. Only the dominant mutant ∆G227, in 
which the signal sequence is inefficiently cleaved, was also partially secreted (lanes 
13 and 14). The reduced molecular weight of the secreted protein indicates that the 
uncleaved pre-pro-vasopressin was retained and only cleaved pro-vasopressin, 
which is identical to wild-type, was allowed to exit. 
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We have previously observed the formation of disulfide-linked products of retained 
∆G227 in COS cells (Beuret et al. 1999). Here, we investigated the formation of 
disulfide complexes for the wild-type and all five pro-vasopressin mutants in COS-1 
and Neuro2a mouse neuroblastoma cells. Transiently transfected cells were 
radiolabeled with [35S]methionine/cysteine for 1 h and then incubated with 
iodoacetamide to alkylate free SH-groups and prevent post-lysis oxidation. 
Vasopressin precursors were immunoprecipitated and separated by gel 
electrophoresis either under non-reducing conditions or after reduction of disulfide 
bonds with β-mercaptoethanol. Under reducing conditions, the precursors expressed 
in Neuro2a cells were found as a ~21 kDa species representing glycosylated pro-
vasopressin (Fig 7B). In contrast, non-reducing conditions (Fig 7C) revealed a ladder 
of bands corresponding in size to prohormone oligomers. Whereas wild-type pro-
vasopressin and the recessive mutant P7L produced less than 20% of high-molecular 
weight forms, the most of the dominant mutant proteins (50–90%) was found in 
covalent oligomers (Fig 7D). Qualitatively the same result was obtained with 
expression in COS-1 cells (not shown), indicating that disulfide-linked oligomerization 
of mutant pro-vasopressin is not a phenomenon specific to neuronal cells. 
The strikingly regular spacing of the disulfide-linked products suggested homo-
oligomerization of the precursor protein. To test this hypothesis, a lane containing the 
non-reduced ∆E47 products was cut out, placed horizontally onto a second gel, and 
overlayed with reducing sample buffer before electrophoresis. All disulfide-linked 
oligomers collapsed to bands of the same mobility as the monomeric protein (Fig 7E). 
The same result was observed for the ∆G227 mutant (not shown). The disulfide-
linked products generated predominantly by the dominant mutants thus represent 
homo-oligomers of glycosylated vasopressin precursor. 
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Fig 7: Disulfide-linked pro-vasopressin homo-oligomers. A: Wild-type (wt) vasopressin precursor and 
the mutants ∆E47, Y2H, P7L, C28Y, and ∆G227were expressed in COS-1 cells, pulse-labeled with 
[
35
S]methionine/cysteine for 1 h, and chased for 2 h. Pro-vasopressin was immunoprecipitated from 
cell lysates (C) and media (M), and analyzed by SDS-gel electrophoresis and autoradiography. The 
positions of marker proteins are indicated with their molecular masses in kDa.  B–E: Untransfected 
Neuro2a cells (–) and cells expressing wild-type (wt) or mutant vasopressin precursor were pulse-
labeled and immunoprecipitated. Precursors were analyzed after reduction of disulfide bonds (panel B) 
or under non-reducing conditions (panel C) by SDS-gel electrophoresis and autoradiography. The 
asterisk indicates the position where the spacer gel ends and the separating gel begins. Panel D 
shows the fraction of disulfide-linked oligomers in percent of the total protein (average and standard 
deviation of three independent experiments). In panel E, ∆E47 products separated in a first dimension 
by non-reducing gel electrophoresis were subjected to a second gel electrophoresis after reduction of 
disulfide bonds. 
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2.3.2 Dominant pro-vasopressin mutants progressively accumulate as ER-
associated aggregates 
To characterize the intracellular localization of the vasopressin precursors, 
transfected COS-1 cells were analyzed by immunofluorescence staining 48 h after 
transfection (Fig 8). COS cells are particularly suitable to visualize intracellular 
organelles and aggregations due to their flat cell body and large cytoplasm. As 
previously shown (Beuret et al. 2004), expression of regulated secretory proteins 
such as granins and prohormones, including pro-vasopressin, is sufficient to 
generate granule-like structures in a variety of nonendocrine cell lines due to 
aggregation in the trans-Golgi. Accordingly, wild-type precursor was concentrated in 
granular accumulations in the cell periphery of about half the expressing cells (Fig 
8A). The recessive mutant P7L showed the same immunofluorescence pattern as the 
wild-type (Fig 8B), which is in agreement with the observation that P7L was not 
retained in the ER, but was secreted into the culture medium as was the wild-type 
prohormone (Fig 7A). 
In many cells, the dominant mutants showed strong reticular staining typical for 
proteins retained in the ER. However, in up to 60% of the transfected cells, they also 
produced condensed accumulations dispersed throughout the cell (Fig 8C, D, E and 
F), with morphologies distinct from that of granule-like structures formed by the wild-
type protein or the recessive P7L mutant. These accumulations had a coarse, short 
tubular (Fig 8C, D, and E) or irregular, laminar appearance (Fig 8F). The different 
morphologies of the aggregates were not specific to particular mutants, but were 
similarly found for all of them. The accumulations were distinct from mitochondria as 
there was no costaining with the mitochondrial marker cytochrome c (not shown). 
To unambiguously distinguish between granule-like structures and accumulations 
formed in the ER, co-staining experiments were performed. When wild-type pro-
vasopressin and other regulated secretory proteins, for example secretogranin II, 
were co-expressed in COS-1 cells, they colocalized in granule-like structures (Beuret 
et al. 2004). This was also the case for the P7L mutant (Fig 9A). By contrast, the 
secretogranin structures and the accumulations of the dominant mutants were clearly 
distinct (shown in Fig 9C for C28Y). When COS-1 cells expressing pro-vasopressin 
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were co-stained with antibodies against NPII and against BAP31 (B cell receptor – 
associated protein 31), an endogenous ER membrane protein, the granule-like 
structures of P7L (like those of the wild-type (Beuret et al. 2004)) were not positive for 
BAP31 (Fig 9B). In contrast, there was extensive co-staining of the C28Y 
accumulations with BAP31 (Fig 9D), indicating that the aggregations produced by the 
dominant mutant are located within the ER. The same was observed with all 
dominant mutants. 
COS-1 cells transfected with the four dominant mutants were analyzed by 
immunofluorescence at different times after transfection (Fig 9E). All mutants 
produced similar results. At 24 h after transfection, anti-NPII immunostaining showed 
the reticular ER pattern, identical to that produced by anti-BAP31 antibody staining, 
in a majority of the cells, whereas less than 30% of transfected cells showed distinct 
aggregates. After 48 and 72 h, the percentage of aggregate-forming cells increased 
to ~55% and ~75%, respectively, and the aggregations generally increased in size. 
As a control, we also analyzed the immunofluorescence staining of COS-1 cells 
expressing an ER-retained mutant of cathepsin Z, a secretory protein with 5 disulfide 
bonds. In these experiments, the frequency of apparent aggregations did not 
increase with time above the control levels of ~ 20%. Large aggregates and disulfide-
oligomers were also produced by dominant vasopressin mutants expressed in CV-1 
cells, the parental cell line of COS-1 cells, lacking the large T-antigen needed for high 
level expression (not shown). Thus, the formation of aggregates was not an artefact 
of excessive expression levels due to plasmid amplification. 
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Fig 8: Intracellular accumulation of wild-type and mutant pro-vasopressin in COS-1 cells. COS-1 cells 
expressing wild-type pro-vasopressin or the indicated mutants were subjected to immunofluorescence 
staining against NPII 48 h post transfection. As expected, approximately half the cells expressing wild-
type pro-vasopressin or P7L produced mostly round granule-like structures (A and B). Conversely, the 
dominant mutants showed accumulations that were mostly elongated or laminar (C–F). The different 
shapes did not correlate with specific mutations. Scale bar, 20 µm.CatZ mut), another ER-retained 
secretory protein. 
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Fig 9: Gradual development of aggregations of dominant pro-vasopressin mutants in the ER. COS-1 
cells expressing the recessive pro-vasopressin mutant P7L (A and B) or the dominant mutant C28Y (C 
and D) were stained 48 h post transfection for NPII in green, and either for cotransfected 
secretogranin II-myc (SgIImyc; A and C) as a marker for granule-like structures, or against 
endogenous BAP31 (B and D) in red. Scale bar, 20 µm. In panel E, COS-1 cells transfected with each 
of the four dominant pro-vasopressin mutants were analyzed by immunofluorescence staining after 24, 
48, or 72 h and the cells with visible aggregates of any kind were quantified. As a control, the 
experiment was performed in parallel for a mutant cathepsin Z (CatZ mut), another ER-retained 
secretory protein. 
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2.3.3 Mutant pro-vasopressin aggregates show filamentous ultrastructure 
COS-1 cells expressing dominant mutants were analyzed by immunogold electron 
microscopy 48 h after transfection (Fig 10). As expected, gold staining was found in 
many cells in ER tubules cut longitudinally or across, some of which had a dilated 
appearance (panels A and A'). Other cells contained multiple large structures of ~1 
µm in diameter decorated with 15-nm gold for pro-vasopressin (panels B, B‘, and C), 
corresponding to the bright accumulations seen by immunofluorescence (Fig 8C, D, 
and E). In some cells, large regions were densely filled with labeled structures (Fig 
10D and D') that might appear almost continuous in immunofluorescence (as in Fig 
8F), adjacent to regions with normal-sized ER tubules of ~60-90 nm diameter. With 
double-labeling, the pro-vasopressin aggregations stained for NPII with 15-nm gold 
were also found to be decorated with 10-nm gold for the ER chaperone calreticulin 
(Fig 10C), confirming that these are ER-derived structures. In some micrographs, the 
core of the aggregates appeared to be structured and gold particles were aligned in 
continuous rows (Fig 10B'), suggesting a filamentous arrangement of the antigen. 
To test their behavior also in a neuronal cell type mimicking the physiological 
situation more closely, dominant pro-vasopressin mutants were expressed in 
Neuro2a cells and analyzed by immunofluorescence and electron microscopy. By 
confocal microscopy, again dispersed accumulations of pro-vasopressin could be 
observed that were strongly costained for the ER chaperone Hsp47 (heat shock 
protein 47; Fig 11). At the ultrastructural level, pro-vasopressin was found by 
immunogold staining in compact accumulations of similar size to those in COS-1 cells 
(Fig 11A and enlarged areas in B and C). The aggregations are structured and 
appear to be composed of tangled filaments of approximately 10–15 nm diameter 
(Fig 12B–F). Using double-labeling, again both mutant pro-vasopressin and 
calreticulin were found to decorate these structures (Fig 12E and F), demonstrating 
that they are derived from the ER. Clearly, aggregations containing mutant pro-
vasopressin are formed not only in fibroblasts, but also in neuronally derived cells, 
which more closely mimic the situation in vivo. 
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Fig 10: Mutant pro-vasopressin aggregations in COS-1 cells visualized by electron microscopy. COS-1 
cells transfected with ∆E47 (A–C) or ∆G227 (D) were analyzed by immunogold electron microscopy 
using 15-nm gold to decorate pro-vasopressin. In panel C, the section was double labeled in addition 
with 10-nm gold for the ER chaperone, calreticulin. Boxed areas in A, B, and D are shown as 
enlargements in A', B', and D'. Arrowheads in panel A' point out dilated ER elements. 
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Fig 11: Accumulation of mutant pro-vasopressin in Neuro2a cells. Differentiated Neuro2a cells 
expressing C28Y pro-vasopressin was stained 48 h post transfection for NPII in green, and for the ER 
chaperone Hsp47 in red and analyzed by confocal microscopy. Scale bar, 20 µm. 
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Fig 12: Fibrillar ultrastructure of mutant pro-vasopressin aggregations in Neuro2a cells. Immunogold 
electron microscopy of Neuro2a cells expressing ∆E47. Pro-vasopressin was stained with 15-nm gold. 
In E and F, in addition to the pro-vasopressin staining the ER marker calreticulin was stained with 10-
nm gold. Boxed areas in A are shown as enlargements in B and C. 
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2.3.4 Purified pro-vasopressin spontaneously forms fibrils after removal of 
denaturant 
To test the ability of pro-vasopressin to form fibrils in isolation, the ∆E47 mutant was 
expressed with a C-terminal His6 tag replacing the signal sequence in Escherichia 
coli, recovered in inclusion bodies, solubilized with 8 M urea, and purified under 
reducing conditions by metal chelate affinity chromatography. After removal of urea 
and reducing agent by dialysis and after pelleting amorphous precipitates by 
centrifugation, fibrillar structures of defined diameter were detected in the 
supernatant by electron microscopy (Fig 13). No fibrils were observed when reducing 
conditions were maintained throughout. These results show that pro-vasopressin can 
form fibrils in vitro in the absence of any other cellular proteins and that oxidation is 
necessary to stabilize them. 
 
Fig 13: In vitro formation of fibrils from purified pro-vasopressin ∆E47. Bacterially expressed pro-
vasopressin ∆E47 with an C-terminal His6-tag was purified by metal chelate affinity chromatography in 
8 M urea and 1 mM DTT. Upon removal of urea and DTT (as described in Materials and Methods), 
fibrils of defined diameter were produced visible by electron microscopy. 
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2.3.5 Cysteine residues are required for aggregate formation 
To investigate whether the formation of disulfide-linked oligomers and of large 
aggregations is dependent on specific cysteines, we generated artificial mutants in 
which the cysteines in any of four segments of the precursor protein were replaced 
by serines or in which all 16 cysteines were mutated (Fig 14A). Mutation of cysteines 
is almost certainly preventing native folding of the precursor. (Indeed, 10 of the 16 
have been found mutated in diabetes insipidus alleles.) These mutants were tested 
for the formation of disulfide-linked oligomers in Neuro2a cells (Fig 14B and C) and of 
aggregates in COS-1 cells (Fig 14D and E). Mutation of any one group of cysteines 
still allowed efficient formation of disulfide oligomers and the appearance of large 
aggregations. None of the cysteines is thus essential for disulfide oligomerization or 
aggregation. As expected, the mutant without any cysteines did not produce covalent 
homo-oligomers (Fig 14B, abcd). This cysteine-less mutant also did not induce the 
formation of aggregates detectable by immunofluorescence above background (Fig 
14D and E). When these mutants were tested for ER retention, two constructs, aBCD 
and abcd, surprisingly were found to be partially secreted into the medium (Fig 14G, 
lanes 10 and 14).  
To exclude the possibility that the absence of aggregates with construct abcd is due 
to reduced ER concentrations, the ER retention signal KDEL was fused to the C-
terminus. This effectively prevented secretion of both aBCDKDEL and abcdKDEL (lanes 
12 and 16). The cysteine-less construct, even when retained in the ER as abcdKDEL, 
did not increase aggregate formation above backgound levels (Fig 14D and E). Even 
at the ultrastructural level, no aggregations could be observed for abcd, but there 
was dispersed staining in the ER (mostly tubular elements in the cytosol and the 
nuclear envelope; Fig 14F). 
To test the ability of the cysteine-free construct to form fibrils in vitro, abcd without the 
signal sequence was expressed in bacteria. Unlike ∆E47 pro-vasopressin, which 
accumulated in inclusion bodies, abcd remained soluble in the bacterial cytoplasm. 
After purification in 8 M urea, dialysis to remove the denaturant and dithiolreitol 
(DTT), and analysis by electron microscopy, hardly any structures resembling the 
fibrillar aggregates as found for ∆E47 in a parallel experiment could be detected (not 
shown). Together with the in vivo results this suggests that, whereas no individual 
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cysteine in the precursor is necessary for oligomerization or aggregation, the 
formation of fibrils and aggregates is dependent on the presence of cysteine 
residues, irrespective of their positions within the precursor protein. 
 
Fig 14: Contribution of cysteines to the formation of aggregates. A: The 16 cysteines in pro-
vasopressin (indicated as black dots) were mutated in groups corresponding to four segments (A, B, 
C, D) to serines (a, b, c, d). s indicates the signal sequence (in these constructs, the pre-pro-
enkephalin signal replaced the natural signal peptide).  B: To analyze the formation of disulfide-linked 
oligomers, Neuro2a cells were transfected with the indicated constructs and labeled for 1 h with 
[
35
S]methionine/cysteine. After alkylation of free SH groups, pro-vasopressin was immunoprecipitated 
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and analyzed by SDS-gel electrophoresis under non-reducing conditions. The experiment with 
untransfected cells (–) reveals the non-specific bands. The positions of molecular weight standards (in 
kDa) are indicated. The absence of cysteines in construct abcd (with a single methionine in NPII) 
accounts for its low labeling signal.  C: The signal of homo-oligomers (arrowheads in panel B; not 
applicable [n.a.] for abcd) were quantified and shown as percent of the total (mean and standard 
deviation of three independent experiments). No specific cysteine cluster was necessary for the 
formation of oligomers.  D: COS-1 cells expressing the indicated constructs were amalyzed by 
immunofluorescence microscopy after staining for pro-vasopressin 2 d after transfection. Typical 
examples are shown. Scale bar, 20 µm.  E: The frequency of aggregate formation was quantified from 
immunofluorescence micrographs as in panel D (mean and standard deviation of three independent 
experiments). Wild-type pro-vasopressin (from the original cDNA [wt] and from the cDNA containing 
silent mutations introducing additional restriction sites [ABCD]) produced post-Golgi granule-like 
structures and were not included in this analysis. Background as determined for mutant CatZ in Fig 9E 
is ~15–20%.  F: Electron micrograph of a Neuro2a cell expressing the cysteine-free construct abcd 
stained for pro-vasopressin with 15-nm gold . Distributed staining on the nuclear envelope and 
cytoplasmic ER is observed, but no aggreagations. N: nucleus.  G: Secretion of the cysteine mutants 





 correspond to aBCD and abcd with a C-terminal ER retention sequence. 
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2.4 Discussion 
2.4.1 Dominant pro-vasopressin mutants cause ER retention due to misfolding 
Many different mutations in the vasopressin precursor have been shown to cause 
diabetes insipidus. Only two of these are recessive. The human P7L mutation in the 
vasopressin nonapeptide (Willcutts, Felner & White 1999) greatly reduces hormone 
binding to its renal receptor, but does not affect precursor folding and secretion. In 
addition, the Brattleboro mutation in rat, a frameshift mutation in the gene segment 
encoding NPII, shows a recessive phenotype (Schmale & Richter 1984). Here, the 
complete absence of a stop codon in the new reading frame results in highly 
inefficient translation of the mutant protein, resulting essentially in a null allele. All 
other known mutations in the vasopressin precursor are dominant, eventually causing 
death of the vasopressin-producing neurons. 
The mutations are diverse and not localized to a specific region in the precursor 
protein, except that no pathogenic mutations have been identified within the C-
terminal glycopeptide. Cytotoxicity appears therefore not to be caused by a specific 
effect of each individual mutation within the prohormone, but to result from 
consequences common to all the mutations. This notion is supported by two 
mutations in the signal sequence, ∆G227 (resulting in a signal truncation; (Beuret et 
al. 1999)) and A(-1)T (mutation of the signal cleavage site (Ito et al. 1993)) In both 
cases, removal of the signal peptide is impaired, but the pro-vasopressin sequence 
itself remains unchanged. A common effect of all dominant mutants tested is their 
retention in the ER, most likely due to misfolding. For frameshift and point mutations 
affecting cysteine residues normally involved in disulfide bonds, misfolding is an 
obvious consequence. Failure to cleave the signal sequence has a more subtle 
effect, as it prevents the N-terminus of the vasopressin sequence from folding into 
NPII, a requirement for the stabilization of the disulfide bond within the hormone 
segment (Beuret et al. 1999; Chen et al. 1992). How can misfolding and ER retention 
cause cytotoxicity? 
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2.4.2 Mutant pro-vasopressins form disulfide-linked homo-oligomers, fibrils 
and large aggregations 
At least half of newly synthesized precursor proteins of all four dominant mutants 
were found to be part of disulfide-linked homo-oligomers. This indicates a specific 
interaction between unfolded pro-vasopressin polypeptides, bringing together 
cysteines to form intermolecular crosslinks. By in vitro mutagenesis, we tested which 
cysteines might be essential for this process. Whereas the presence of some 
cysteines was required for the formation of disulfide-linked oligomers as well as 
aggregations visible by immunofluorescence, no single cysteine was specifically 
necessary. 
Disulfide-linked homo-oligomers were also observed for wild-type pro-vasopressin 
and the recessive mutant P7L, but to a much lower extent. Not yet folded protein 
appears to be transiently crosslinked into disulfide-linked homo-oligomers, but 
subsequently to be rescued when the free molecules successfully fold into the native 
structure. Indeed, even the mutant proteins are not irreversibly trapped in disulfide 
aggregates because we have previously found them to be quite efficiently degraded 
by the cytosolic proteasome (Friberg, Spiess & Rutishauser 2004). Only a small 
fraction thus escapes ER-associated degradation to accumulate in large aggregates 
visible by fluorescence and electron microscopy. Consistent with this, it takes 2–3 
days for a majority of expressing cultured cells to develop visible aggregates.  
Electron microscopic analysis showed that the pro-vasopressin accumulations have a 
fibrillar ultrastructure. The ability of pro-vasopressin to form ordered, linear polymers 
by self-assembly was confirmed in vitro with bacterially expressed and purified 
protein. The vasopressin precursor thus resembles a whole family of proteins that 
generate amyloid fibers and are associated with neurodegenerative disorders. 
 
2.4.3 A model for the formation of fibrillar aggregates in the ER 
Taken together, our results suggest a model for aggregate formation in ADNDI as 
illustrated in Fig 15. Upon translocation into the ER lumen, vasopressin precursor 
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might acquire a conformation that leads to homo-oligomers which are stabilized by 
intermolecular disulfide-links between exposed cysteine residues. This process is 
reversible and thus allows wild-type proteins to fold into their native structure and exit 
the ER, and allows folding-deficient mutants to be retrotranslocated into the cytosol 
for proteasomal degradation. A significant fraction of mutant precursors accumulate 
as growing oligo- and polymers, forming fibrils and eventually large visible 
aggregates aqssociated with ER chaperones. 
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Fig 15: Model for the development of fibrillar aggregates in the ER. Pre-pro-vasopressin is synthesized 
into the ER to undergo folding and quality control. Natively folded precursor leaves the ER and exits 
the cell via the secretory pathway and secretory granules. Misfolded precursor may either be 
retrotranslocated for subsequent proteasomal degradation, or form specific oligomers and polymers, 
stabilized by disulfide-links (in red), growing to fibrils and generating inclusions within the ER, visible 
by light microscopy. 
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2.4.4 Role of aggregates for cytotoxicity 
The formation of fibrillar aggregations and inclusion bodies are frequent pathological 
features of neurodegenerative disorders (Ross & Poirier 2005). In contrast to the 
extensively studied aggregations associated with Alzheimer's, Parkinson's, and 
Huntington's disease that are extracellular, cytoplasmic, or intranuclear, the 
aggregations formed by dominant pro-vasopressin mutants are produced within the 
lumen of the ER. 
The role of aggregation in degenerative disease processes is controversial because 
there is often no direct correlation between the amount of inclusions and cell 
degeneration (Chun et al. 2002; Ross & Poirier 2005). The formation of large 
aggregates and inclusion bodies might represent a cellular protective response and 
early protofibrils might be the neuropathogenic species triggering disease (Lansbury 
& Lashuel 2006; Ross & Poirier 2005). In a diabetes insipidus knock-in mouse 
expressing the cytotoxic pro-vasopressin mutant C67X, induction of the ER 
chaperone BiP was detected, but no obvious aggregations were apparent (Russell et 
al. 2003). No upregulation of the ER stress-induced proapoptotic transcription factor 
C/EBP homologous protein (CHOP) or other evidence for apoptosis was observed. 
However, aggregate-producing cells might have been rapidly eliminated. In contrast, 
vasopressinergic neurons expressing the same C67X mutant in transgenic rats were 
resistant to a cytotoxic effect, but produced distended ER structures containing the 
mutant protein and markers of autophagy (Davies & Murphy 2002; Si-Hoe et al. 
2000). This lysosomal degradation mechanism is thought to protect against toxic 
effects of altered or aggregated intracellular proteins (Martinez-Vicente & Cuervo 
2007). Inhibition of autophagy was found to compromise viability of C67X-expressing 
rat neurons and Neuro2a cells (Castino et al. 2005). Interestingly, we could not detect 
significant colocalization of the dominant mutant C28Y with Lamp1 or LC3 (markers 
for lysosomes and autophagosomes respectively) neither in COS-1 nor Neuro2a cells 
(unpublished results). It remains to be analyzed in detail to which extent the disulfide-
linked homo-oligomers of pro-vasopressin mutants detected biochemically and the 
large aggregations observed by light and electron microscopy contribute to 
cytotoxicity. 
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2.5 Materials and methods 
2.5.1 Plasmids and constructs 
The cDNAs of the human wild-type vasopressin precursor and the mutants ∆G227, 
∆E47, and C67X, as well as of myc-tagged secretogranin II have been described 
before (Beuret et al. 1999; Friberg, Spiess & Rutishauser 2004). The cDNAs 
encoding the vasopressin mutants Y2H and P7L were a gift from Jane Christensen 
(Århus University Hospital, Denmark). The C28Y mutant was generated by 
polymerase chain reaction. The expression plasmid of human pre-pro-cathepsin Z 
mutant (N184Q, N224Q) (Appenzeller-Herzog et al. 2005) was a gift from Hans-Peter 
Hauri and Beat Nyfeler (Biozentrum, University of Basel). All human cDNAs were 
subcloned into the pRc/RSV expression plasmid (Invitrogen). 
The 16 cysteines in pro-vasopressin were mutated to serines by PCR mutagenesis. 
For this purpose, the signal sequence was replaced by that of pre-pro-enkephalin as 
described (Cescato et al. 2000; Friberg, Spiess & Rutishauser 2004), providing a 
BsrGI restriction site near the start of pro-vasopressin. Silent mutations were 
introduced to insert a KpnI site at codons 49/50 of the pro-vasopressin coding 
sequence and a BamHI site at codons 64/65. Together with a natural SmaI site at 
codons 27/28 and external SalI site, these restriction sites served to clone and 
recombine PCR amplified mutant segments. All constructs were verified by DNA 
sequencing. 
 
2.5.2 Cell culture and transient transfection 
COS-1 cells were grown in Dulbecco‘s modified Eagle‘s medium (DMEM; Sigma) 
supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin, 100 g/ml 
streptomycin, 2 mM L-glutamine at 37°C in 7.5% CO2. COS-1 cells were transiently 
transfected in 6-well plates using Lipofectine (Life Technologies) or FuGENE HD 
(Roche) and analyzed 2–3 days after transfection or as indicated. Neuro2a cells were 
grown in DMEM containing 4500 mg/l glucose, supplemented as above. They were 
transfected using Metafectene (Biontex Laboratories). To induce differentiation, cells 
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were cultured from 1 d before transfection in 1 mM valproic acid in DMEM with 3% 
fetal calf serum, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine. 
 
2.5.3 Metabolic labeling and immunoprecipitation 
For labeling experiments, transfected cells were starved for 30 min. in DMEM without 
methionine and cysteine (Sigma) supplemented with 2 mM L-glutamine. Cells were 
labeled with 100 µCi/ml [35S]protein labeling mix (PerkinElmer) and chased with 
excess methionine and cysteine. Cells were washed in phosphate-buffered saline 
(PBS), lysed in 500 µl of lysis buffer (PBS, 1% TritonX-100, 0.5% deoxycholate, 2 
mM phenylmethylsulfonylfluoride), and scraped. Cell lysates or media were incubated 
with rabbit polyclonal anti-NPII (Friberg, Spiess & Rutishauser 2004) in lysis buffer 
containing 1 mM phenylmethylsulfonylfluoride, 0.5% SDS and 1 mg/ml BSA. Bound 
proteins were immunoprecipitated with protein A-Sepharose (Zymed) and analyzed 
by electrophoresis on 10% polyacrylamide Tris/tricine SDS-gels and 
autoradiography. 
 
2.5.4 Analysis of disulfide-linked oligomers 
Transfected and labeled cells were washed with cold PBS containing 100 mM 
iodoacetamide, incubated at 4°C for 1 h in the dark with 200 l 200 mM Tris, pH 8.0, 
100 mM iodoacetamide, 2mM phenylmethylsulfonyl fluoride, lysed in lysis buffer 
containing 100 mM iodoacetamide, and immunoprecipitated. One half of each 
sample was boiled in SDS-sample buffer with and the other half without β-
mercaptoethanol before gel electrophoresis and autoradiography. The amount of 
protein present as disulfide-linked aggregates (signal of high molecular weight 
oligomers as percent of total signal for each construct) was quantified by 
phosphorimager. 
For analysis in the second-dimension, a lane containing a non-reduced sample was 
cut out and soaked in sample buffer containing 200 mM β-mercaptoethanol for 1 min. 
The gel strip was then loaded horizontally onto a second Tris/tricine SDS-gel, whose 
Part I:  Dominant pro-vasopressin mutants that cause diabetes insipidus form disulfide-linked fibrillar 
aggregates in the endoplasmic reticulum  57 
stacking gel was supplemented with 50 mM β-mercaptoethanol, and overlayed with 
reducing sample buffer for electrophoresis. 
 
2.5.5 Immunofluorescence 
Transfected cells were grown for 24–72 h on glass coverslips, fixed with 3% 
paraformaldehyde for 30 min at room temperature, washed in PBS, permeabilized 
and blocked with 0.1% saponin, 20 mM glycine, 1% bovine serum albumin (BSA) in 
PBS for 20 min, incubated at room temperature with primary antibodies for 2 h in 
PBS containing 0.1% saponin, 20mM glycine and 1% BSA; washed, and stained with 
fluorescent secondary antibodies in PBS containing 0.1% saponin for 30 min After 
several washes with saponine/PBS, the coverslips were mounted in Mowiol 4-88 
(Hoechst). As primary antibodies, we used the polyclonal rabbit anti-NPII antiserum, 
mouse monoclonal anti-myc antibody 9E10, and a mouse monoclonal antibody 
against the endogenous ER membrane protein BAP31 (a gift from Hans-Peter Hauri; 
(Klumperman et al. 1998)). As secondary antibodies, non-cross-reacting Cy3-labeled 
goat anti-mouse and Cy2-labeled goat anti-rabbit immunoglobulin antibodies 
(Jackson Immunoresearch and Amersham Biosciences, respectively) were used 
according to the manufacturers‘ recommendations. Staining patterns were analyzed 
with a Zeiss Axioplan 2 microscope with a Leica DFC420C imaging system or for 
Neuro2a cells with a Zeiss Confocal LSM510 Meta microscope. 
 
2.5.6 Electron microscopy 
Cultured cells were fixed in 3 % formaldehyde and 0.2% glutaraldehyde for 2 h at 
room temperature and after addition 1% picric acid overnight at 4°C, scraped, 
pelleted, resuspended and washed 3 times in PBS, treated with 50 mM NH4Cl in PBS 
for 30 min to quench free aldehydes, and washed 3 times in PBS. The final pellet 
was resuspended in 2% warm agarose and left on ice to solidify. Agarose pieces 
were dehydrated and infiltrated with LR-gold resin (London Resin, London, UK) 
according to the manufacturer's instructions and allowed to polymerize for 1 day at 
4°C. For immunogold labeling, sections of about 60 nm were collected on carbon-
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coated Formvar-Ni-grids, incubated with rabbit anti-NPII in PBS, 2% BSA, 0.1% 
Tween-20 for 2 h, washed with PBS, and incubated with 15-nm colloidal gold-
conjugated goat anti-rabbit immunoglobulin antibodies (BioCell, Cardiff) in PBS, 2% 
BSA, 0.1% Tween-20 for 90 min Grids were washed 5 times for 5 min in PBS and 
then 5 times in H2O, before staining for 10 min in 2% uranylacetate followed by 1 min 
in Reynolds lead citrate solution. Sections were viewed in a Phillips CM100 electron 
microscope. 
For double labeling, the first labeling was performed using rabbit anti-human 
calreticulin antibody (Stressgen) and 10-nm colloidal gold-conjugated goat anti-rabbit 
immunoglobulin antibodies as described above. After washing 6 times for 2 min with 
PBS, the sections were fixed again for 2 h with 1% formaldehyde and 1% 
glutaraldehyde in PBS, washed with PBS, and quenched for 10 min with 50 mM 
NH4Cl. The sections were incubated with PBS, 2% BSA, 0.1% Tween-20 for 10 min 
followed by incubation for 90 min with rabbit anti-NPII immunoglobulins that had been 
purified from serum by a protein A–Sepharose column (Amersham Pharmacia 
Biotech), pre-coupled to 15-nm gold–protein A (BioCell) at a molar ratio of 2:1, and 
incubated with a twofold excess of unrelated mouse IgG. Grids were washed and 
stained as above. As negative controls to ensure specificity of labeling, cells were 
stained as above, except that 15-nm gold–protein A was used that had not been 
loaded with anti-NPII immunoglobulins. This produced very low background labeling 
(not shown). 
 
2.5.7 Bacterial expression and in vitro fibril formation 
For bacterial expression, the coding sequence of ∆E47 and cysteine-free (abcd) pro-
vasopressin (without the signal sequence) were cloned into the plasmid pET21b 
(Novagen) and thus provided with a C-terminal His6 tag. The proteins were expressed 
in E. coli BL21(DE3) after induction with 1 mM isopropyl-D-thiogalactoside for 2–3 h, 
solubilized from inclusion bodies (∆E47) or the cytosol fraction (abcd) in 8 M urea, 10 
mM Tris-HCl, pH 8, 1 mM DTT, and protease inhibitors (10 µg/ml each of leupeptin, 
pepstatin and aprotinin, 0.5 mM orthovanadate, 1 mM PMSF), and purified by Ni-NTA 
chromatography. Protein at 1 mg/ml was dialyzed stepwise for 8–16 h each to 6, 5, 4, 
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2, 1 and 0.5 M urea, and finally to 10 mM Tris-HCl, pH 7.4, 100 mM NaCl without 
DTT overnight. Large precipitates were removed by centrifugation in a tabletop 
centifuge for 5 min. The supernatant was analyzed by electron microscopy. 10 µl 
were adsorbed to Formvar carbon-coated Ni grids, washed, dried, stained with 0.5% 
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3 Part II: Aggregates of mutant vasopressin 
precursors: an amyloid-like structure? 
3.1 Introduction 
3.1.1 Amyloids 
Many neurodegenerative diseases including Alzheimer‘s, Parkinson‘s, and 
mammalian prion disease are characterized by the formation of fibrillar protein 
aggregates (Kelly 1996). They are usually formed by normally soluble proteins, which 
assemble into insoluble fibers. These fibers are generally resistant to proteolytic 
digestion. In Alzheimer‘s disease, accumulation of amyloid fibers and their deposition 
in plaques has long been associated with cell death and disease progression. 
However, there is recent evidence suggesting the non fibrillar protein oligomers to be 
the cytotoxic species (Bucciantini et al. 2002; Kayed et al. 2003). 
High-resolution solid state nuclear magnetic resonance (NMR) studies and X-ray 
crystallography revealed the structure of amyloid fibrils formed by several proteins 
(Jaroniec et al. 2004; Luca et al. 2007; Petkova, Yau & Tycko 2006; Sawaya et al. 
2007; Walsh et al. 2009). All these structures share a common cross-β architecture, 
in which β-strands run perpendicular to the fibril axis. The β-sheets self-assemble 
into protofilaments, which may comprise a bundle of twisted β-sheets, which further 
packs into amyloid fibers (Sunde & Blake 1998). 
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Fig 16: Structural model for the protofilament in Aβ1–40 fibrils:  a) All-atom representation of a pair of 
peptide molecules. Residues 10–22 and 30–40 have β-strand conformations, forming two separate in-
register, parallel β-sheets. The protofilament is a four-layered β-sheet structure with C2 symmetry 
about its long axis.  b) Average structure resulting from 10 independent molecular dynamics/energy 
minimization runs on a cluster of 12 peptide molecules, with interatomic distance and backbone 
torsion angle restraints dictated by solid-state NMR data. Hydrophobic, polar, negatively charged, and 
positively charged side-chains are colored green, purple, red, and blue respectively.  c) and d) Cartoon 
representations, with residues 12–21 in red and residues 30–40 in blue (Tycko 2006) 
 
3.1.2 Disruption of β-sheets by proline insertions 
Proline is a very potent candidate to disrupt β-sheet formation. Minor and Kim (1994) 
showed that the amino acids glycine and proline have a very low propensity to form 
β-sheets. This property has been used to determine the regions important for amyloid 
formation in different proteins. Williams et al. (2004) generated a series of single-
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proline replacement mutants of Amyloid(A)β(1–40), and determined the 
thermodynamic stabilities of amyloid fibrils formed from these mutants to characterize 
the susceptibility of different residue positions of the Aβ sequence to proline 
substitution. Their results suggested that the Aβ peptide, when engaged in the 
amyloid fibril, folds into a conformation containing three highly structured segments, 
consisting of contiguous sequence elements 15–21, 24–28, and 31–36, that are 
sensitive to proline replacement and thus likely to include the β-sheet portions of the 
fibrils. 
Abedini and Raleigh (2006) designed and compared a triple proline mutated peptide 
variant of the amyloidogenic 8–37 region of the human islet amyloid polypeptide 
(hIAPP) with proline substitutions at positions 17, 19 and 30. They could show, that 
proline residues outside the 20–29 region reduce ordered fibril formation significantly. 
Rauscher et al. (2006) analyzed diverse sequences, including those of elastin 
amyloids, spider silks, wheat gluten, and insect resilin. This analysis revealed a 
threshold in proline and glycine composition, above which amyloid formation was 
impeded and elastomeric properties became apparent. 
Parrini et al. (2005) found that glycine residues are highly conserved in the 
acylphosphatase-like structural family. They constructed six variants of human 
muscle acylphosphatase (AcP), where six glycines were exchanged to alanine. All six 
mutants were enzymatically active and had conformational stabilities similar to those 
of other mutants with non-conserved residues. However, all variants, with the 
exception of one were found to form amyloid aggregates more rapidly than the wild-
type protein under both native and denaturing conditions. Glycine residues have a 
high level of conformational flexibility and a high entropic cost associated with their 
secondary structure formation. The authors thus concluded that the high level of 
conversion of these four glycine residues in this structural family arises from the need 
to possess inhibitors of aggregation at strategic positions, which act at both the 
unfolded and folded levels. 
In Parkinson‘s disease the protein α-synuclein forms fibrillar structures enriched in 
the core of so-called Lewy bodies, a histologically defining lesion of Parkinson‘s 
disease. It has been shown that incorporation of prolines, especially in the region 
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spanning residues 37-89 of α-synuclein, reduces fibril formation (Koo, Lee & Im 
2008). 
 
3.1.3 Proline/glycine substitution in pro-vasopressin 
Since we could show that none of the 4 groups of cysteines of the precursor was 
exclusively necessary for aggregation of pro-vasopressin (section 2.3.5), we 
suggested that disulfide bonds were only important to stabilize the fibrils. Thus, the 
question arose which part of the protein sequence itself could promote aggregation 
and fibril formation. Due to the apparently ordered structure of the fibrils formed in 
vitro (2.3.4, Fig 13), formation of an amyloid-like structure can be suggested. 
In order to define the sequence necessary for aggregation of pro-vasopressin, 10 
mutants were designed. In these mutants sequential stretches of 10 amino acids 
were substituted by the following sequence: PGPGPGTPGP (Fig 17) (a single 
threonin was included to facilitate cloning), thereby disrupting any potential 
aggregation promoted by the respective amino acid stretch. 
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3.2 Material and methods 
3.2.1 Cloning strategy: 
The Pro constructs were cloned from pECE vasopressin wild type as template using 
the following primers: 
Table 2: Primers for Pro mutants 
































Forward flanking primer for the N-terminal portion: GAAGTAGTGAGGAGGC (ECEleft) 
Reverse flanking primer for the C-terminal portion: CTACAAATGTGGTATGGC (ECEright) 
The PCR products were purified from a 1% agarose gel using the NucleoSpin gel 
extraction kit (Macherey-Nagel) according to the manufacturer‘s protocol. The 
purified constructs were cut with the restriction enzyme Asp718 (Roche) for the N-
terminal product and BsrGI (NEB) for the C-terminal product. After gel 
electrophoresis and purification, the products were mixed and ligated using T4 ligase 
(Roche). The ligase was inactivated at 60°C. PCR was performed on the ligation 
product using the flanking primers ECEleft and ECEright and the Expand PCR 
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system (Roche). The product was cut from an agarose gel, digested with HindIII and 
XbaI (Roche) and ligated into the pRc/RSV expression vector. 
 
3.2.2 Cultivation and Transient Transfection of COS-1 cells 
COS-1 cells were grown in Dulbecco‘s modified Eagle‘s medium (DMEM, Sigma) 
supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine at 37°C in 7.5% CO2. 
The cells were transiently transfected in 6-well plates using polyethylenimin (PEI, 
Sigma). 240 µl complete DMEM were mixed with 8 µl PEI (Stock 1 mg/ml 25 kDa) 
and 1.5 µg DNA and incubated for 45 min at room temperature. 560 µl complete 
DMEM were added to the transfection mix and added to the cells. The medium was 
changed the next day, and the cells were analyzed two to three days after 
transfection. 
 
3.2.3 Metabolic labeling and immunoprecipitation 
48 h post transfection the cells were starved for 30 min in 500 µl DMEM without 
methionine and cysteine (Sigma) supplemented with 2 mM L-glutamine. Cells were 
labeled with 100 µCi/ml [35S]protein labeling mix (PerkinElmer) im DMEM for another 
30min. The labeling medium was removed and the cells washed with PBS. 500 µl 
chase medium containing an excess of methionine and cysteine were added and 
chased for 2 h. Cells were washed again with cold medium and lysed for 20 min with 
lysis buffer (1% Triton X-100, 0.5% Deoxycolate, 2 mM PMSF in PBS). Cells were 
scraped into a tube an incubated for 1 h on ice. After lysis, the mixture was 
centrifuged to remove the cellular debris and the supernatant and the medium were 
incubated over night with lysis buffer containing 1 mM PMSF, 0.5% SDS, 1 mg/ml 
BSA and rabbit polyclonal anti-NPII (Friberg, Spiess & Rutishauser 2004). The 
protein was precipitated using protein A-Sepharose (Zymed) for 30 min and washed 
several times with lysis buffer containing 1 mM PMSF, 1% SDS and 1 mg/ml BSA 
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followed by 2 washes with PBS. The precipitate was mixed with 100 µl 2x SDS 
sample buffer containing β-mercapto ethanol and cooked for 10 min. The samples 
were analyzed by electrophoresis on 10% polyacrylamide Tris/tricine SDS-gels and 
autoradiography. 
 
3.2.4 Metabolic labeling and non-reducing immunoprecipitation 
Metabolic labeling was performed as described above. After starvation and labeling 
the cells were washed with PBS containing 100 mM iodoacetamide (Fluka). The cells 
were incubated at 4°C for 1 h in the dark with 200 µl 200 mM Tris, pH 8.0, 100 mM 
iodoactamid and 2 mM PMSF. The cells were lysed by adding 500 ml lysis buffer 
(described above) containing 100 mM iodoacetamide for 1 h in the dark. The mixture 
was centrifuged for 15 min to remove cellular debris and the supernatant was mixed 
with 1 mg/ml BSA and rabbit polyclonal anti-NPII (Friberg, Spiess & Rutishauser 
2004) overnight. The protein was precipitated using protein A-Sepharose (Zymed) for 
30 min and washed several times with lysis buffer containing 1 mM PMSF, 1% SDS, 
1 mg/ml BSA and 50 mM iodoactemide, followed by 2 washes with PBS containing 
50 mM iodoactemide. The precipitate was mixed with 100 µl 2x SDS sample buffer 
without β-mercaptoethanol and cooked for 10 min. The samples were analyzed by 
electrophoresis on 10% polyacrylamide Tris/tricine SDS-gels and autoradiography. 
 
3.2.5 Immunofluorescence 
Cells were grown on coverslips and transfected as mentioned above. 48 h post 
transfection the cells were washed 3 times in PBS and fixed in 3% paraformaldehyde 
(Fluka) for 20 min. To prevent autofluorescence, the cells were quenched in 50 mM 
NH4Cl in PBS for 10 min. Permeabilization was achieved using 0.1% Triton X-100 
and 1% BSA in PBS for 15 min. The cells were stained using rabbit polyclonal anti-
NPII (Friberg, Spiess & Rutishauser 2004) as primary antibody in 0.1% Triton X-100 
and 1% BSA in PBS for 2 h in the dark. The cells were washed 4 times in PBS and 
stained with non-crossreacting Cy2 labeled goat anti rabbit (Jackson 
 Part II: Aggregates of mutant vasopressin precursors: an amyloid-like structure?  67 
Immunoresearche) according to the manufacturers recommendations. The coverslips 
were washed in PBS and mounted in Mowiol 4-88 (Hoechst). Analysis was 




3.3.1 Proline/glycine replacements cause retention of the precursor in the ER 
but do not prevent the formation of disulfide-linked oligomers 
To test the secretion ability of the Pro-mutants in COS-1 cells, transiently transfected 
cells were radiolabeled with [35S]methioninen/cysteine for 30 min and chased with 
excess unlabeled methionine/cysteine for 2 h. Cells and media were subjected to 
immunoprecipitation using anti-neurophysin II antiserum followed by SDS-gel 
electrophoresis an autoradiography (Fig 17B). The wild-type proteins and the 
mutants Pro1-10 (Fig 17A) were visualized as major species of 21 kDA, 
corresponding to N-glycosylated pro-vasopressin. The mutant Pro1, in which the first 
ten aminoacids after the signal peptide were mutated appeared as a larger product 
compared to glycosylated pre-pro-vasopressin (Fig 17B). This difference in size 
resulted from inhibited cleavage of the signal peptide due to the Pro at position +1 
(Nilsson & von Heijne 1992; Barkocy-Gallagher & Bassford 1992). After 2 h of chase, 
wild-type pro-vasopressin was secreted into the medium but not the Pro mutants, 
indicating that Pro1-10 had been retained. 
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Fig 17: A: proline mutagenesis of the vasopressin precursor: stretches of ten amino acids were 
exchanged by a proline/glycine rich sequence (red),  B: Wild-type (wt) vasopressin precursor and the 
Pro mutants 1-10 were expressed in COS-1 cells, pulse-labeled with [
35
S]methionine/cysteine for 1 h, 
and chased for 2 h. Pro-vasopressin was immunoprecipitated from cell lysates (C) and media (M), and 
analyzed by SDS-gel electrophoresis and autoradiography. The positions of marker proteins are 
indicated with their molecular weights in kDa. 
In order to characterize the Pro mutants in terms of their ability to form of disulfide-
linked oligomers, transiently transfected COS-1 cells were radiolabeled with 
[35S]methionine/cysteine for 30 min and treated with iodoacetamide to prevent post-
lysis oxidation. After immunoprecipitation and separation by SDS-gel electrophoresis 
under non-reducing conditions, all Pro mutants showed significant formation of 
disulfide-linked oligomers compared to the wild-type (Fig 18). This finding suggests 
that oligomer formation is not prevented by the inclusion of proline/glycine rich 
segments. 
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Fig 18: To analyze the formation of disulfide-linked oligomers, COS-1 cells were transfected with the 
indicated constructs and labeled for 1 h with [
35
S]methionine/cysteine. After alkylation of free SH 
groups, pro-vasopressin was immunoprecipitated and analyzed by SDS-gel electrophoresis under 
non-reducing conditions. The positions of molecular weight standards (in kDa) are indicated. 
 
3.3.2 Proline insertion within the vasopressin domain inhibits formation of 
large aggregates 
Proline/glycine insertion throughout the precursor sequence did not prevent the 
formation of disulfide-linked oligomers. To define the sequence involved in the 
formation of large aggregates, transiently transfected COS-1 cells were analyzed by 
immunofluorescence 72 h post transfection with the Pro mutants and the wild-type as 
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a control (Fig 19A). Only mutant Pro1, in which the first 10 amino acids were 
replaced by a proline/glycine rich sequence showed a reduction in the formation of 
visible aggregates, suggesting this region to be engaged in the formation of stable 
complexes (Fig 19B). 
 
Fig 19:  A: COS-1 cells expressing the indicated constructs were amalyzed by immunofluorescence 
microscopy after staining for pro-vasopressin 3 d after transfection. Representative cells are shown. 
Scale bar, 20 µm.  B: The frequency of aggregate formation was quantified from immunofluorescence 
micrographs as in panel A (mean and standard deviation of three independent experiments. 
Background as determined for mutant CatZ in Fig 9E is ~15–20%.   
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3.4 Discussion 
Fibrillar protein aggregates are a hallmark of many neurodegenerative diseases like 
Alzheimer‘s or prion disease. Usually soluble proteins assemble to insoluble fibres 
which are resistant to proteolytic cleavage. Depositions of these protein 
accumulations have long been thought to be associated with cell death and disease 
progression. However the pathogenic nature of these accumulations is still debated. 
Studies have also suggested that the toxic species may be the small oligomers rather 
than the large aggregates which may even represent a protection mechanism 
(Goldberg & Lansbury Jr 2000; Haass & Steiner 2001). 
 
3.4.1 Insertion of 10 prolines and glycines inhibits the formation of large 
aggregates 
A common feature of amyloids is their cross-β architecture, in which β-strands run 
perpendicular to the fibril axis (Sunde & Blake 1998) . These strands assemble into 
protofilaments which then comprise a structure resembling a bundle of twisted β-
sheets. Many studies reported that insertion of proline and glycine caused disruption 
of β-sheets. (Minor & Kim 1994; Rauscher et al. 2006; Koo, Lee & Im 2008). 
We constructed 10 artificial mutants of the vasopressin precursor where we inserted 
stretches of proline and glycine (P/G) to perform a scan for regions on the precursor 
necessary for aggregation and disulfide-linked oligomerisation. Only one of our 
proline constructs was able to disrupt the formation of large aggregates in COS-1 
cells. In this construct, the vasopressin moiety was replaced by proline and glycine. 
The result suggests that the vasopressin domain is necessary for the formation of 
large aggregates. Beuret et al. (1999) found that the naturally occurring mutant with a 
truncation in the signal sequence ( G227) causes reduced cleavage of the signal 
peptide. In the resulting precursor, vasopressin is not able to fold into its binding 
pocket of NPII and disulfide linked oligomers as well as large aggregates (Fig 8) are 
formed, although NPII is folded and only vasopressin moiety is available. This 
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suggests that vasopressin is sufficient for the formation of disulfide linked oligomers 
and large aggregates which fits to our data. 
The fact that the formation of disulfide-linked oligomers was not influenced by the 
insertion of a P/G rich sequence at any site suggests that disulfide-linked 
oligomerisation alone is not sufficient to initiate assembly of oligomers into fibres. 
Disulfide-linked oligomerisation might be also triggered by more than one site on the 
precursor. Since our approach would only be able to inactivate one of these sites at a 
time, we would not be able to see an effect on disulfide-linked oligomerisation.  
To address this question, new constructs will be necessary. Since it is very likely that 
one of the sites sufficient for oligomerisation lies within the vasopressin moiety, new 
constructs would contain the replacement of the vasopressin domain for a P/G rich 
sequence as in mutant Pro1 in combination with additional sequential segments 
replaced by P/G. This would give rise to 9 additional constructs, screening for two 
putative sites necessary for oligomerisation. However, it is still possible that formation 
of disulfide-linked oligomers is not diagnostic for DI mutants. Still, this approach could 
provide further insights into the mechanism of aggregation in ADNDI. 
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4 Part III: Molecular analysis of novel 
mutations causing autosomal dominant 
neurohypophyseal diabetes insipidus 
4.1 Introduction 
The genetic linkage between ADNDI and the vasopressin gene was established by 
Repaske et al. (1990). Ito et al. (1991) described the first mutation in the pro-
vasopressin gene in a Japanese family affected by ADNDI. Interestingly, most 
mutations fall within the coding sequence for NPII; a few signal mutations and 
mutations in vasopressin itself are known, but none fall within the coding sequence 
for the glycopeptide. The mutations that affect the precursor include both missense 
mutations changing a single amino acid, and nonsense mutations which truncate the 
precursor. No differences in clinical presentation have been described for individuals 
with different dominant mutations, and penetrance is high. 
In cooperation with a group of Belgian pediatricians, we analyzed DNA samples from 
various patients with ADNDI and their relatives for mutations in the pro-vasopressin 
gene. One of these mutations was cloned and expressed in COS-1 cells. 
 
4.2 Material and methods 
4.2.1 Genomic DNA analysis in ADNDI patients 
Each of the three exons of the vasopressin-NPII gene was amplified from genomic 
DNA by polymerase chain reaction (PCR) using a Biometra T3 thermocycler in 10% 
dimethyl sulfoxide (DMSO) using the Expand High Fidelity PCR System (Roche). 
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The following primers were used for amplification: 
TGCCTGAATCACTGCTGACCGCTGGGGACC forward PCR primer for genomic vasopressin ex.1  
GCTATGGCTGCCCTGAGATGGCCCACAGTG reverse PCR primer for genomic vasopressin ex.1  
TCGCTGCGTTCCCCTCCAACCCCTCGACTC forward PCR primer for genomic vasopressin ex.2+3  
CCTCTCTCCCCTTCCCTCTTCCCGCCAGAG reverse PCR primer for genomic vasopressin ex. 2+3  
 
40 cycles of melting (94°C for 1 min), annealing (55°C for 1 min), and extension 
(72°C for 3 min) were carried out, with a final 15 min at 72°C for extension. PCR 
products were run on 1% agarose gels, then the bands were excised and extracted 
from agarose using a commercial kit (NucleoSpin Gel extraction; Macherey-Nagel). 
Following purification of the PCR product, the nucleotide sequences of both coding 
and non-coding DNA strands were determined using the following primers: 
TGCCTGAATCACTGCTGACCGCTGGGGACC forward PCR primer for genomic vasopressin ex.1  
GCTATGGCTGCCCTGAGATGGCCCACAGTG reverse PCR primer for genomic vasopressin ex.1  
TCGCTGCGTTCCCCTCCAACCCCTCGACTC forward PCR primer for genomic vasopressin ex.2  
CCTCTCTCCCCTTCCCTCTTCCCGCCAGAG reverse PCR primer for genomic vasopressin ex. 3  
CGCCCCCCCCCAGGCCCGCCCCCGCCGCGC reverse sequencing primer for genomic vasopressin ex. 2 
CCCAGGCGCCCGTGCTCACACGTCCTCCCG forward sequencing primer for genomic vasopressin ex. 3  
 
4.2.2 Plasmids and constructs 
One of the mutants discovered by sequencing was cloned for further analysis. The 
cDNA of the human wild-type vasopressin precursor has been described before 
(Beuret et al., 1999; Friberg et al., 2004). The C28Y (as a control) and C61W 
mutants were generated by polymerase chain reaction. All human cDNAs were 
subcloned in the pECE expression plasmid. The constructs were confirmed by 
automated sequencing. 
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4.2.3 Cell culture and transient transfection 
COS-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma) 
supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 µg/ml 
streptomycin, 2 mM L-glutamine at 37 °C in 7.5% CO2. The cells were transiently 
transfected in 6-well plates using polyethylenimine (Sigma) and analyzed 2 days after 
transfection. 
 
4.2.4 Metabolic labeling and immunoprecipitation 
For labeling experiments, transfected cells were starved for 30 min in DMEM without 
cysteine and methionine (Sigma) supplemented with 2 mM L-glutamine. Cells were 
labeled for 30 min with 100 µCi/ml [35S]-protein labeling mix (PerkinElmer Life 
Sciences) in starvation medium and chased in starvation medium supplemented with 
excess cysteine and methionine. Cells were transferred to 4 °C, washed with PBS, 
lysed in 500 µl of lysis buffer (PBS, 1% Triton X-100, 0.5% deoxycholate, 2 mM 
phenylmethylsulfonyl fluoride), and scraped. After 10 min of centrifugation in a 
microcentrifuge, the lysate was subjected to immunoprecipitation using rabbit 
polyclonal anti-neurophysin II (Friberg et al., 2004). The immune complexes were 
isolated with protein A-Sepharose (Zymed Laboratories Inc.) and analyzed by 
electrophoresis on 10% polyacrylamide Tris/Tricine SDS-gels and autoradiography. 
 
4.2.5 Immunofluorescence 
Transfected cells were grown for 48 h on glass coverslips, fixed with 3% 
paraformaldehyde for 20 min at room temperature, washed with PBS, permeabilized 
and blocked with 0.1% saponin, 1% bovine serum albumin (BSA) in PBS for 20 min, 
incubated at room temperature with primary antibodies for 2 h in saponin/BSA/PBS, 
washed, and stained with fluorescent secondary antibodies in saponin/PBS for 30 
min. After several washes with saponin/PBS, the cover slips were mounted in Mowiol 
4-88 (Hoechst). As primary antibodies we used the polyclonal rabbit anti-NPII 
antiserum and monoclonal antibody against the endogenous ER chaperone calnexin 
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(BD Bioscience). As secondary antibodies we used Cy2-labeled goat anti-rabbit and 
Cy3-labeled goat anti-mouse (Jackson Immunoresearch) according to the 
manufacturers‘ recommendation. Staining was analyzed using a Zeiss Axioplan 2 
microscope with a Leica DFC420C imaging system. 
 
4.3 Results 
4.3.1 Direct sequence analysis of patient samples 
Genomic DNA samples from 3 families with healthy and affected members were 
analyzed. For each person, exon 1, 2 and 3 were amplified, and both strands were 
sequenced. Amplification yielded fragments of 345 bp and 732 bp, respectively. In all 
patients a heterozygous single base substitution was detected, whereas all healthy 
family members showed wild-type sequence. 
Patient 1 had developed DI as an infant. She carried a novel mutation of a G to a T at 
nucleotide 1919 (1919 G > T, genomic nucleotide numbering beginning with the A of 
initial ATG) in exon 2 (Fig 20). This mutation alters codon 77 from GAG to TAG, 
substituting glutamine for a stop codon, resulting in a truncated precursor.  
 
 
Fig 20: Genomic sequence of vasopressin-NPII in patient 1 showing a substitution of G to T at nucleotide 1919 
(arrowhead) 
 
Patient 2 is a member of a family with three affected and two asymptomatic family 
members. All affected members carried a novel mutation of a C to a G at nucleotide 
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1720 (1720 C > G, genomic nucleotide numbering beginning with the A of ATG) in 
exon 2. This mutation alters codon 10 from TGC to TGG (Fig 21B), resulting in a 
substitution of cysteine 10 for tryptophan. 
 
Fig 21: Genomic sequence of vasopressin-NPII in patient 2 (panel A) and an unaffected family member, showing 
a substitution of C to G at nucleotide 1720 (arrowhead) 
 
Patient 3 is a member of a family with two asymptomatic and three affected family 
members (Fig 22). Each affected individual carried a novel a mutation of a C to a G 
at nucleotide 1873 (1873 C > G, genomic nucleotide numbering beginning with the A 
of initial ATG) in exon II (Fig 23 panel B). This mutation alters codon 61 of NPII from 
TGC to TGG, substituting cysteine 61 for tryptophan, C61W. 
 
Fig 22: pedigree of a family with 3 affected members: squares: males, circles: females, closed symbols: affected 
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Fig 23: Genomic sequence of vasopressin-NPII in patient 3 (panel B) showing a substitution of C to G at 
nucleotide 1873 (arrowhead) and an unaffected family member (panel A) 
 
4.3.2 Mutant pro-vasopressin is retained 
To assay secretion, wild-type pro-vasopressin, the known dominant mutant C28Y 
and the novel mutant C61W were expressed in COS-1 cells, pulse labeled with 
[35S]methionine/cysteine, chased for 2 h, isolated from the cells and from the media 
by immunoprecipitation, and analyzed by SDS-gel electrophoresis and 
autoradiography. In contrast to the wild-type pro-vasopressin, where a considerable 
fraction could be recovered from the medium, the C28Y and C61W mutants were 
completely retained in the cell (Fig 24). 
Part III:  Molecular analysis of novel mutations causing autosomal dominant neurohypophseal diabetes 
insipidus   79 
 
Fig 24: secretory capacity of mutant and wild-type pro-vasopressin: COS1 cells expressing the wild type and the 
two mutants C28Y and C61W were labeled with [35S]methionine/cysteine for 30 min and chased for 2 h. Pro-
vasopressin was immunoprecipitated from cell lysates (C) and media (M), and analyzed by SDS-gel 
electrophoresis and autoradiography. The positions of marker proteins are indicated with their molecular weights 
in kDa. 
 
4.3.3 Localization of mutant pro-vasopressin 
To characterize the intracellular localization of the C61W precursor, transfected 
COS-1 cells were analyzed by immunofluorescence staining 48 h after transfection. 
In many cells expressing C61W, a strong reticular staining typical for proteins 
retained in the ER was visible. However, a considerable number of cells also showed 
larger aggregations, typical for mutant pro-vasopressin (see also Part I, Fig 8). These 
inclusions were of round, sometimes short tubular appearance and stained positive 
for the ER marker calnexin (Fig 25). 
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Fig 25: Intracellular accumulation of C61W pro-vasopressin in COS-1 cells. COS-1 cells vasopressin 
C61W were subjected to immunofluorescence staining against NPII 72 h post transfection. More than 
half of the expressing cells showed accumulations that were mostly round or elongated (panel B). The 
remaining cells showed a reticular staining typical for ER retained protein (panel A). Scale bar, 20 µm. 
 
4.4 Discussion 
Here, we present three additional ADNDI families with novel mutations in the 
vasopressin gene. In total, 58 pro-vasopressin mutations causing DI are now known 
(Table 3). The clinical presentation in patients with different mutations is similar and 
all affected individuals usually manifest with polyuria and polydipsia within their first 
months or years of life. 
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1 225  AG  SP -19 to -16  del MPDT 1 (Christensen et al. 2004) 
 227  GA  SP -19 to -16  del MPDT 1 (Christensen et al. 2004) 
 227  del G  SP -19 to -16  del MPDT 1 (Rutishauser et al. 1996) 
 274  CT  SP -3  SF 1 (Rittig et al. 1996) 
 
279  GA  SP -1  AT 8 
(Ito et al. 1993) 
(McLeod et al. 1993) 
(Rittig et al. 1996) 
(Calvo et al. 1998) 
(Siggaard et al. 1999) 
(Boson et al. 2003) 
(Christensen et al. 2004) 
 
280  CT  SP -1  AV 3 
(Rittig et al. 1996) 
(Heppner et al. 1998) 
(Christensen et al. 2004) 
 
285  TC  VP 2  YH 2 
(Rittig et al. 1996) 
(Rittig et al. 2002) 
 286  AC  VP 2  YS 1 (Kobayashi et al. 2006) 
 287-289  del CTT  VP 3  del F 1 (Wahlstrom et al. 2004) 
       
2 1720  CG  NP 10  CW 1 This work 
 1730  GC  NP 14  GR 1 (Rittig et al. 1996) 
 1740  GT  NP 17  GV 1 (Bahnsen et al. 1992) 
 1748  CT  NP 20  RC 1 (Rittig et al. 1996) 
 1751  TC  NP 21  CR 1 (Goking et al. 1997) 
 
1757  GC  NP 23  GR 3 
(Heppner et al. 1998) 
(Rutishauser et al. 2002) 
(Christensen et al. 2004) 
 1757  GA  NP 23  GR 1 (Calvo et al. 1999) 
 1758  CT  NP 23  GV 1 (Gagliardi, Bernasconi & Repaske 1997) 
 1761  CT  NP 24  PL 1 (Repaske & Browning 1994) 
 1770  GT  NP 27  CF 1 (Wolf et al. 2003) 
 1772  TC  NP 28  CR 1 (Hansen, Rittig & Robertson 1997) 
 1773  GA  NP 28  CY 1 (Skordis et al. 2000) 
 1774-1776  del CGC  NP 28/29  del C/ AW 1 (Flück et al. 2001) 
 1797  TC  NP 36  VA 1 (Christensen et al. 2004) 
 
1824-1829  del GAG  NP 47  del E 7 
(Yuasa et al. 1993) 
(Rittig et al. 1996) 
(Mahoney et al. 2002) 
(Christensen et al. 2004) 
(Ye et al. 2005) 
 1829  GA  NP 47  EK 1 (Miyakoshi et al. 2004) 
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1830  AG  NP 47  EG 2 
(Rittig et al. 1996) 
(Christensen et al. 2004) 
 1839  TC  NP 50  LP 1 (Rittig et al. 1996) 
 1857  CT  NP 56  SF 1 (Grant et al. 1998) 
 
1859  GA  NP 57  GS 2 
(Ito et al. 1991) 
(Rittig et al. 1996) 
 1859  GC  NP 57  GR 1 (Rittig et al. 1996) 
 1859  GT  NP 57  GV 9 (de Melo et al. 2008) 
 
1872  GC  NP 61  CS 2 
(Rittig et al. 1996) 
(Bullmann et al. 2002) 
 
1872  GA  NP 61  CY 2 
(Grant et al. 1998) 
(Rutishauser et al. 2002) 
 
1873  CA  NP 61  CX 3 
(Rittig et al. 1996) 
(Grant et al. 1998) 
(Christensen et al. 2004) 
 1873  CG  NP 61  CW 3 This work 
 1874  GT  NP 62  GW 1 (Nagasaki et al. 1995) 
 
1883  GT  NP 65  GC 2 
(Rittig et al. 1996) 
(Christensen et al. 2004) 
 1884  GA  NP 65  GD 1 (Christensen et al. 2004) 
 
1884  GT  NP 65  GV 2 
(Ueta et al. 1996) 
(Rauch et al. 1996) 
 1886  CT  NP 66  RC 1 (Rutishauser et al. 1999) 
 1887  GC  NP 66  RP 1 (Mundschenk et al. 2001) 
 1889  TA  NP 67  CS 1 (Baglioni et al. 2004) 
 1889  TG  NP 67  CG 1 (DiMeglio et al. 2001) 
 1890-1891 GCCT  NP 67  CS 2 (Davies et al. 2005) 
 1891  CA  NP 67  CX 1 (Nagasaki et al. 1995) 
 1892  GC  NP 68  AP 1 (Elias et al. 2003) 
 1907  TG  NP 73  CG 1 (Christensen et al. 2004) 
 1908  GT  NP 73  CF 1 (Santiprabhob, Browning & Repaske 2002) 
 1910  TC  NP 74  CR 1 (Rutishauser et al. 2002) 
 1911  GA  NP 74  CY 1 (Fujii, Iida & Moriwaki 2000) 
 1919 GT  NP 77  EX 1 This work 
       
3 2094  CA NP 79  CX 1 (Rittig et al. 1996) 
 2101  GT NP 82  EX 2 (Calvo et al. 1999) 
 2106-2107  CGGT NP 83  EX 2 
(Rittig et al. 1996) 
(Bullmann et al. 2002) 
 2110  TG NP 85  CG 2 
(Abbes et al. 2000) 
(Nijenhuis et al. 2001) 
 2110  TC NP 85  CR 1 (Abbes et al. 2000) 
 2112  CG NP 85  CW 1 (Christensen et al. 2004) 
 2116  GT NP 87  EX 1 (Rittig et al. 1996) 
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Out of the 58 different mutations in the coding sequence, 55 are causing different 
amino acid sequence alterations. 6 mutations are located in the signal sequence, 3 of 
them leading to deletion of the first methionine. The resulting signal peptide is 
truncated and products of these mutations show less efficient cleavage of the signal 
peptide. 3 mutations are located in the vasopressin sequence and 49 mutations are 
found in the NPII sequence. There are no sequence alterations known to be located 
within the sequence of the glycopeptide. There are 6 mutations causing deletions, 7 
nonsense mutations and 45 missense mutations. In 22 cases a cysteine is affected, 
this represents a proportion of approximately 40%. This high percentage of cysteines 
points out the importance of cysteines in proper precursor folding and suggests 
cysteines to play a major role in ADNDI. 
All these mutations have in common that they very likely interfere with protein folding 
and as a consequence with ER export. This is most obvious in truncations where 
entire regions necessary for folding are deleted, or in cases where a cysteine is 
mutated, preventing proper disulfide formation. A more particular case is represented 
by the deletion of the initial methionine. This has shown to cause truncation of the 
signal sequence. Translation thus starts at a methionine at position (-16), resulting in 
a cleavage defect (Beuret et al. 1999). This is similar to the mutation A(-1)T (Ito et al. 
1993). The uncleaved signal prevents binding of the N-terminal vasopressin into its 
binding pocket of NPII. Several mutations involve the vasopressin binding sites of 
NPII including Glycine 14, Glycine 17, Glycine 23, Arginine 20, Proline 24, Glutamate 
47, and Leucine 50 of NPII (Gagliardi, Bernasconi & Repaske 1997). 
We showed that several mutants cause oligomerization (Beuret et al. 1999) and 
aggregation (see Part I Fig 8) of the mutant precursor which is hypothesized to cause 
cytotoxicity (Rittig et al. 1996; Ito et al. 1993; Ito & Jameson 1997). Accumulation of 
mutant vasopressin pro-hormone has been shown to cause an aberrant ER 
morphology (Nijenhuis, Zalm & Burbach 1999; Si-Hoe et al. 2000), thus it is likely to 
disturb the function of the ER and thus also the viability of the cell. Decreased 
viability of the magnocellular neurons producing vasopressin would explain the 
autosomal dominant inheritance of ADNDI. There are several observations 
supporting the possible mechanism for ADNDI. Strong reductions in the amount of 
magnocellular neurons in the paraventricular and suprapoptic nuclei of the 
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hypothalamus was observed autopsies of ADNDI patients (Braverman, Mancini & 
McGoldrick 1965; Nagai et al. 1984; Gaupp 1941; Hanhart 1940; Bergeron et al. 
1991). It has also been shown that mutant vasopressin precursors caused 
cytotoxicity in stably transfected Neuro2a cells (Ito & Jameson 1997) and in a knock-
in mouse model (Russell et al. 2003). 
The 3 novel mutations described here fit into this pattern: mutation of cysteine 77 to 
stop in NPII, mutation of cysteine 10 to tryptophan, mutation of cysteine 61 to 
tryptophan. Metabolic labeling of transiently transfected COS-1 cells showed the 
C61W mutation to be not secreted after 2 hours, but retained inside the cell. The site 
of retention was identified by immunofluorescence studies as the ER, shown by 
colocalization with the ER marker calnexin. The staining revealed patterns ranging 
from reticular to bigger accumulations of NPII. 
Our findings strengthens the hypothesis that there is no link of ADNDI to a specific 
set of mutations in the vasopressin gene, since all the mutations described above 
cause ADNDI, possibly due to misfolding and aggregation. How aberrant precursor 
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5 General Discussion 
5.1 Aggregation of mutant pro-vasopressin 
Mutations in the pro-vasopressin gene causing DI are inherited in a dominant 
manner. This dominance is most likely due to cytotoxicity of the precursor leading to 
massive loss of vasopressinergic magnocellular neurons, which results in low or 
undetectable circulating levels of vasopressin. We were able to show that mutant 
vasopressin precursors are retained in the ER. This is a common effect of dominant 
DI mutations, independent from their nature or location. It is very likely that all of 
them are retained due to misfolding. We could also show that DI mutants form 
intracellular aggregates of mutant protein. Analysis under higher magnification by 
electron microscopy revealed a fibrillar substructure within the protein accumulations. 
In vitro expression of the vasopressin precursor confirmed the ability of pro-
vasopressin to self assemble into ordered, linear polymers. This connects ADNDI to 
a whole group of neurodegenerative diseases characterized by the formation of 
protein aggregates and amyloid fibers. 
Many proposals regarding the mechanism of toxicity induced by protein aggregations 
have been made (Ross & Poirier 2005). Aggregated proteins could inhibit the 
proteasome as shown for α-synuclein in Parkinson‘s disease (Tanaka et al. 2001). 
Another possible mechanism of toxicity could be impairment of autophagy, since 
mutant α-synuclein has been reported to impair chaperone-mediated autophagy 
(Cuervo et al. 2004). During the aggregation process aberrant proteins could interact 
with or even recruit other cellular constituents, thereby inactivating them. Finally, 
exposure of hydrophobic patches could cause interactions with other cellular 
components, for example cellular membranes, potentially leading to the formation of 
pores. 
In contrast to Alzheimer‘s, Parkinson‘s or Huntington‘s disease where aggregates are 
found extracellularly, in the cytosol, or nucleus, aggregates of pro-vasopressin are 
located in the ER. Nevertheless the above mentioned mechanisms of action may 
similarly apply. Direct inhibition of the proteasome as discussed above is unlikely, 
since it has been shown that mutant pro-vasopressin is retrotranslocated and 
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degraded by the proteasome (Friberg, Spiess & Rutishauser 2004). Impairment 
would rather take place at the site of retrotranslocation. Accumulations of mutant pro-
vasopressin could partly get stuck in the retrotranslocon and thus cause persistent 
blockage. Another possible mechanism could be the recruitment and sequestration of 
proteins important for proper ER function, mainly chaperones. During the aggregation 
process, mutant pro-vasopressin might recruit large amounts of chaperones like 
calnexin, calreticulin or PDI, making them unavailable for other proteins during their 
synthesis. Improperly folded pro-vasopressin could expose hydrophobic patches 
which could form pores in the ER membrane. Such pores would destroy the ER 
membrane, causing massive Ca2+ leakage into the cytoplasm which triggers 
apoptosis. 
For the oligomerization process of mutant pro-vasopressin, cysteines turned out to 
be required by forming intermolecular disulfide crosslinks. However, no single 
cysteine is specifically necessary to form disulfide-linked oligomers and large protein 
aggregates. The formation of disulfide-linked oligomers was also observed in cells 
expressing either wild-type pro-vasopressin or the recessive mutant P7L; however, 
oligomerisation happened on a much lower level. This suggests that disulfide 
crosslinking of the precursor is a transient event and thus can be resolved again, e.g. 
by PDI, enabling the protein to assume its native structure. However, higher 
concentrations of mutant unfolded precursor promote the formation of homo-
oligomers, since folding is not possible.  
Importance of covalent crosslinks in neurodegenerative diseases has been reported 
for Cu/Zn-superoxide dismutase (SOD1) in a familial form of amyotrophic lateral 
sclerosis (ALS), where point mutations in SOD1 are the cause for neurodegeneration 
(Rosen et al. 1993; Deng et al. 1993). Aggregates of mutant SOD1 proteins are 
observed in histopathology and are invoked in several proposed mechanisms for 
motor neuronal death (Johnston et al. 2000). SOD1 contains 4 cysteine residues. 
Mutations in the SOD1 gene were reported to induce the formation of an incorrect 
disulfide bond upon mild oxidative stress. This intermolecular disulfide bond was 
shown to be important for high molecular weight aggregates in the cytosol. Recent 
biochemical studies suggest that it is the immature disulfide-reduced forms of the 
familial ALS mutant SOD1 proteins that play a critical role; these incorrect forms tend 
to misfold, oligomerize, and readily undergo incorrect disulfide formation. It is not 
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known how the disulfide bridge is formed in the reducing environment of the cytosol 
(Niwa et al. 2007).  
Another example for the formation of covalent intermolecular crosslinks in 
neurodegeneration is the protein huntingtin. Expanded CAG repeats in the huntingtin 
gene are the cause for Huntington‘s disease. The disease manifests when 40 or 
more consecutive glutamines are present in the protein. Transglutaminases cause 
oligomerisation via transamination between huntingtin molecules, leading to protein 
aggregates in the nucleus and the cytoplasm (Kahlem, Green & Dijan 1998).  
Andringa et al (2004) showed that in Parkinson‘s disease, α-synuclein is also 
covalently crosslinked by tissue transglutaminases. In vitro experiments showed that 
transglutaminase 1, 2 and 5 specifically crosslinked glutamine 99 and lysine 58. As 
shown by Thioflavine T fluorescence monitoring, the formation of this crosslink 
accelerated the aggregation of native α-synuclein in Lewy bodies (Nemes et al. 
2009). Taken together these findings suggest that covalent crosslinks in aggregation 
diseases are more widespread than previously assumed. 
 
5.2 The vasopressin domain of the precursor is necessary for 
aggregation but not oligomerisation 
In order to further characterize the aggregation mechanism, we were looking for 
other factors influencing the aggregation competence of the vasopressin precursor. 
We already showed that cysteines play an important role in aggregation since 
replacement of all 16 cysteines by serines abolished aggregate formation. However, 
since no specific group of cysteines seemed to exquisitely promote aggregate 
formation, we were looking for a sequence necessary for aggregation. For this 
purpose we performed a proline/glycine scan where we replaced sequential stretches 
of 10 amino acids by a sequence riche of prolines and glycines (P/G). Surprisingly, 
the analysis of the resulting 10 mutant vasopressin precursors revealed that the 
formation of disulfide-linked homo-oligomers was not abolsihed by prolines. 
However, the formation of large aggregates was specifically prevented if the 
vasopressin domain was replaced by a P/G rich sequence, indicating that the 
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determinants for aggregation are located in the nonapeptide vasopressin and that 
oligomerisation not necessarily culminates in formation of large aggregates. 
The detailed mechanism for the formation of fibrillar amyloid-like aggregates is not 
entirely clear. The first step is always represented by protein misfolding, followed in a 
second step by formation of protein oligomers. The process finally culminates in the 
formation of fibrils. Additionally, several other structures have been described to be 
part of the protein misfolding and aggregation process, including soluble oligomers, 
pores, annular structures, spherical micelles and protofibrils (Glabe & Kayed 2006; 
Caughey & Lansbury 2003; Haass & Selkoe 2007). There are studies supporting the 
notion that an intermediate-ordered oligomers rather than the fibrillar endproduct 
represents the pathogenic protein (Goldberg & Lansbury Jr 2000; Haass & Steiner 
2001). The hypothesis that primarily early aggregates exhibit toxicity also provides an 
explanation for the poor correlation between inclusion bodies and other visible 
aggregates and the severity of neurodegenerative diseases such as Alzheimer‘s 
(Terry et al. 1991) or Parkinson‘s (Tompkins & Hill 1997). An assay to measure 
toxicity of dominant DI mutants would provide information about the toxic aggregate 
species in ADNDI. It remains to be further investigated to which extent disulfide-
linked homo-oligomers and the larger aggregations in ADNDI contribute to 
cytotoxicity. Further analysis of the mechanisms and consequences of aggregation 
may provide deeper insight into the mechanisms leading to cytotoxicity in ADNDI. 
 
5.3 Aggregation of mutant vasopressin precursors: a premature 
physiological event? 
Although amyloids are associated with more than two-dozen human diseases, there 
are also amyloids with native biological activities. The Escherichia coli protein ―curli‖ 
forms extra-cellular amyloid fibrils which are involved in surface and cell-cell contact 
(Barnhart & Chapman 2006). Pmel17 is a melanocyte protein necessary for 
eumelanin deposition in mammals and is found in melanosomes in a filamentous 
form. It forms a functional human amyloid that is important in the formation of skin 
pigmentation. An increasing number of proteins with no link to protein deposition 
diseases has been found to form, under some conditions in vitro, fibrillar aggregates 
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that have the morphological and structural properties classifying them as amyloid 
fibrils, e.g. endostatin or stefin B (Stefani & Dobson 2003). These results suggest that 
the ability to form amyloid fibrils is a generic property of many peptides and proteins. 
Maji et al. (2009) proposed a model in which amyloid formation of peptide hormones 
is important and contributes to normal cell and tissue physiology. They analyzed 42 
peptide hormones for their capacity to form amyloids and found 10 to be capable. 
Among them was the nonapeptide vasopressin. According to this model, transient 
aggregation of vasopressin into amyloid like structures is part of the maturation 
process of dense core secretory vesicles. The lower pH of the TGN and secretory 
granules causes vasopressin to exit its binding pocket of NPII and amyloid formation 
is initiated. Upon vasopressin leaving its binding pocket, prohormone convertase 
clipps the protein. The amyloid formed by vasopressin is desintegrated upon fusion 
of the secretory granule with the plasma membrane due to increase in pH in 
extracellular conditions. This model would propose a physiological role of amyloid 
formation. The finding of Maji et al. (2009) could explain previous and recent findings 
in ADNDI. Beuret et al. (1999) analyzed the molecular consequences of a mutation 
( G227) that destroys the translation initiation codon. The precursor was completely 
retained within the ER but the uncleaved signal did not affect folding of the 
neurophysin portion. Preventing disulfide formation in the vasopressin nonapeptide 
by mutation of cysteine 6 to serine was shown to be sufficient to cause disulfide 
oligomerization and retention. The present data extend these earlier findings and 
confirms that pro-vasopressin is still able to aggregate even when NPII is folded and 
that vasopressin is the portion promoting aggregation. This would also fit to our 
findings that aggregate formation was disrupted by exchanging the vasopressin 
portion by a stretch of prolines and glycines (Fig 19). The role of the disulfide bond 
formation, however, would be to act as a stabilizing factor for aggregate formation, 
since conditions in the ER (pH7.4) are different from those in the TGN (pH 6.2) and 
granules (pH5.5). The higher pH of the ER resembles more extracellular conditions. 
Thus formation of pro-vasopressin amyloids in the ER without a stabilizing factor may 
be not possible. 
Taken together, our finding could represent a premature aggregation event which 
takes place in the ER in contrast to the physiological aggregation event in the Golgi 
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as described by Maji et al. (2009). In the ER, aggregates cannot be resolved 
anymore. Important for aggregation initiation is a high concentration of the hormone. 
Mutant precursors can accumulate over time and thus form amyloid-like aggregates 
in the ER. 
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